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Abstract: Kidney transplantation is the best therapy option for patients with end stage renal disease.
But patients receiving a graft from a genetically non-identical donor are at a constant risk of rejection.
The actual treatment for an organ recipient therefore aims to induce a systemic immunosuppression,
which is very potent in inhibition of acute rejections. The long-term outcome of renal transplants, how-
ever, is still hampered by the toxicities of these regimens and their disability to prevent chronic allograft
rejection. Furthermore, the systemic immunosuppression leads to a higher risk for infections and/or
cancer. Therefore, new strategies for more specifc and less toxic treatments for recipients of renal grafts
are needed. A major goal of research is the induction of donor-specifc tolerance. A promising tool to
achieve both is costimulation blockade. Costimulation in addition to recognition of the cognate anti-
gen is needed to fully activate a T cell. A variety of costimulatory pathways are described and their
blockade has been shown to be beneficial in models for solid organ transplantation. Costimulation is
also important during the interaction of a T cell with its target. Renal tubular epithelial cells (rTECs),
which are the major target of cytotoxic T lymphocytes during kidney allograft rejection, do also express
costimulatory molecules under inflammatory conditions. One of the most important costimulatory path-
ways in both processes is the CD40-CD154 pathway. A more recently described costimulatory molecule
expressed on T cells is DNAM-1. In section 1 we evaluate the role of CD40 expressed on donor cells for
the direct alloresponse during the priming and the effector phase in vitro. We show that donor CD40 is
important for induction of allospecific Th1, Th17 and cytotoxic T cells. In an in vivo model for renal
allograft rejection we show that renal allografts from CD40 deficient donors are partially protected from
the effects of acute rejection. Studies blocking the CD40- CD154 pathway so far mostly used blocking
antibodies against CD154. The translation of such an agent to the clinics has resulted in thromboem-
bolic events in patients and is thus not pursued anymore. In mice the blockade of CD40 itself however
is not possible with the antibodies available today. In section 2 we therefore present the development
of an F(ab)-fragment against murine CD40 with exclusively antagonistic properties. F(ab)86 is able to
prevent CD40 triggered B cell activation and proliferation and reduces allospecific T cell proliferation
in vitro. DNAM-1 is a costimulatory molecule expressed on T and NK cells. Its two ligands CD155
and CD112 are expressed on several cell types, also in the kidney. In section 3 we show that DNAM-1
ligands are expressed on rTECs. We detected a role for DNAM-1 during allospecific T cell priming but
not during cytotoxic activity against rTECs. Furthermore, we could exclude that ligation of CD155
and CD112 enhances T cell activity during allospecific priming or cytotoxicity against rTECs. The in
vitro results are further strengthened by the finding that renal allografts deficient in CD155 and CD112
are not protected from rejection. Summing up, this study gives a deeper insight into the role and rel-
evance of the CD40 and DNAM-1 pathways during renal allograft rejection and suggests a new tool to
block murine CD40. Transplantation ist die beste Therapie für Patienten mit Nierenversagen. Aber
Patienten die ein Transplantat von einem genetisch unterschiedlichen Spender erhalten tragen ein dauer-
haftes Risiko, ihr Transplantat abzustossen. Die momentane Strategie, um das zu verhindern, ist eine
systemische Immunsuppression, welche akute Abstossungen erfolgreich zu verhindern vermag. Die ver-
wendeten Medikamente besitzen jedoch toxische Nebenwirkungen und sind nicht in der Lage chronische
Abstossungen zu verhindern. Weiterhin tragen diese Patienten aufgrund der Immunsuppression ein er-
höhtes Risiko für Infektionen und/oder Krebserkrankungen. Es ist also notwendig, gezieltere und weniger
toxische Therapieoptionen zu finden. Eine weitere Option ist die Induktion von immunologischer Toler-
anz spezifisch für das transplantierte Organ. Eine mögliche Strategie, um beide Ziele zu erreichen, ist die
Costimulations-Blockade. T Zellen benötigen für eine vollständige Aktivierung nicht nur ein Signal durch
den T-Zell-Rezeptor, sondern zusätzlich costimulatorische Signale. Mehrere costimulatorische Signalwege
sind inzwischen beschrieben. Sie zu blockieren hat sich in mehreren Modellen für Organtransplantation
als förderlich erwiesen. Doch auch für die Interaktion zwischen T Zelle und Zielzelle spielt Costimulation
eine Rolle. Renale Tubulus- Epithelzellen (rTECs) sind Zielzellen für allospezifische zytotoxische T Zellen
während der Abstossng eines Nierentransplantats. Sie exprimieren costimulatorische Moleküle unter in-
flammatorischen Bedingungen. Ein wichtiger costimulatorischer Signalweg für beide erwähnten Vorgänge
ist der CD40-CD154-Signalweg. Weiterhin wurde DNAM-1 als costimulatorisches Molekül auf T Zellen
identifiziert. In Abschnitt 1 untersuchen wir die Rolle von CD40 auf Spender-Zellen während der T Zell
Aktivierungs- und Effektorpahse in vitro. Wir zeigen, dass Donor-CD40 eine Rolle für die Induktion von
Th1, Th17 und zytotoxischen T Zellen spielt. In einem in vivo-Modell für Nierentransplantation fanden
wir weiterhin, dass Transplantate von CD40-defizienten Spendern trotz akuter Abstossung eine bessere
Funktion aufweisen. Die meisten Studien, in denen der CD40-Signalweg bisher blockiert wurde, basierten
auf der Nutzung eines Antikörpers gegen CD154. Als ein solcher Antikörper zum ersten Mal in Patien-
ten verwendet wurde, traten jedoch thromboembolische Komplikationen auf, die eine solche Therapie
unmöglich machen. In Mausmodellen ist es bisher nicht möglich gewesen CD40 selbst zu blockieren, da
alle verfügbaren Antikörper agonistisch wirken. In Abschnitt 2 zeigen wir daher die Entwicklung eines
F(ab)-Fragments gegen Maus-CD40, das ausschliesslich antagonistische Eigenschaften besitzt. F(ab)86
war in vitro in der Lage CD40-mediierte B Zell Aktivierung und allospezifische T Zell-Proliferation zu
supprimieren. DNAM-1 ist ein costimulatorisches Molekül, das auf T und NK Zellen exprimiert wird.
Seine zwei Liganden CD155 und CD112 werden auf verschiedenen Zelltypen exprimiert, unter anderem
in der Niere. In Abschnitt 3 zeigen wir, dass CD155 und CD112 auf rTECs exprimiert werden. Wir
konnten weiterhin feststellen, dass DNAM-1 eine Rolle während der allospezifischen T Zell Aktivierung
spielt. Für die Zytotoxizität gegen rTECs hingegen wird DNAM-1 nicht benötigt. Letztlich konnten wir
ausschliessen, dass die beiden Liganden CD155 und CD112 einen Einfluss auf allospezifische Aktivierung
oder Zytotoxizität gerichtet gegen rTECs haben. Diese in vitro Ergebnisse konnten wir in einem in vivo-
Modell erhärten. Nierentransplantate von CD155- oder CD112-defizienten Spendern sind nicht vor der
Abstossung geschützt. Zusammenfassend können wir mit dieser Arbeit die Rolle von CD40 und DNAM-
1 während der Abstossung von Nierentransplantaten genauer erkärenl und eine Strategie präsentieren,
um murines CD40 zu blockieren.
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APC antigen presenting cell
CML cell-mediated lympholysis
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CTLA-4 cytotoxic T lymphocyte antigen 4
d day
DAG diacylglycerol
DC dendritic cell
DNAM-1 DNAX accessory molecule-1
DST donor-specific transfusion
EAE experimental autoimmune encephalomyelitis
FACS fluorescence-activated cell sorting
HLA human leukocyte antigen
ICAM-1 intercellular adhesion molecule-1
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IFN interferon
IL interleukin
IP3 inositol triphosphate
LFA-1 lymphocyte function associated antigen-1
MACS magnetic cell separation
MAPK mitogen activated protein kinase
MFI mean fluorescence intensity
MHC major histocompatibility complex
MS multiple sclerosis
mTOR mammalian target of rapamycin
necl nectin like
NFκB nuclear factor κB
NFAT nuclear factor of activated T cells
PD-1 programmed cell death-1
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PIP2 phosphatidylinositol bisphosphate
PKC protein kinase C
PLC-γ phospholipase C-γ
PMA phorbol12-myristate13-acetate
PTLD post-transplant lymphoproliferative disorder
qPCR quantitative PCR
rTEC renal tubular epithelial cell
SLE systemic lupus erythematosus
STAT signal transducer and activator of transcription
TCR T cell receptor
Th T helper cell
TLR toll-like receptor
TNF tumor necrosis factor
TNF-R tumor necrosis factor-receptor
TRAF TNF-R associated factor
Summary
Kidney transplantation is the best therapy option for patients with end stage
renal disease. But patients receiving a graft from a genetically non-identical
donor are at a constant risk of rejection. The actual treatment for an organ
recipient therefore aims to induce a systemic immunosuppression, which is very
potent in inhibition of acute rejections. The long-term outcome of renal trans-
plants, however, is still hampered by the toxicities of these regimens and their
disability to prevent chronic allograft rejection. Furthermore, the systemic im-
munosuppression leads to a higher risk for infections and/or cancer. Therefore,
new strategies for more specific and less toxic treatments for recipients of renal
grafts are needed. A major goal of research is the induction of donor-specific
tolerance. A promising tool to achieve both is costimulation blockade.
Costimulation in addition to recognition of the cognate antigen is needed to
fully activate a T cell. A variety of costimulatory pathways are described and
their blockade has been shown to be beneficial in models for solid organ trans-
plantation. Costimulation is also important during the interaction of a T cell
with its target. Renal tubular epithelial cells (rTECs), which are the major
target of cytotoxic T lymphocytes during kidney allograft rejection, do also ex-
press costimulatory molecules under inflammatory conditions. One of the most
important costimulatory pathways in both processes is the CD40-CD154 path-
way. A more recently described costimulatory molecule expressed on T cells is
DNAM-1.
In section 1 we evaluate the role of CD40 expressed on donor cells for the direct
alloresponse during the priming and the effector phase in vitro. We show that
donor CD40 is important for induction of allospecific Th1, Th17 and cytotoxic
T cells. In an in vivo model for renal allograft rejection we show that renal
allografts from CD40 deficient donors are partially protected from the effects of
acute rejection. Studies blocking the CD40-CD154 pathway so far mostly used
blocking antibodies against CD154. The translation of such an agent to the
clinics has resulted in thromboembolic events in patients and is thus not pur-
sued anymore. In mice the blockade of CD40 itself however is not possible with
the antibodies available today. In section 2 we therefore present the develop-
ment of an F(ab)-fragment against murine CD40 with exclusively antagonistic
properties. F(ab)86 is able to prevent CD40 triggered B cell activation and
proliferation and reduces allospecific T cell proliferation in vitro. DNAM-1 is
a costimulatory molecule expressed on T and NK cells. Its two ligands CD155
and CD112 are expressed on several cell types, also in the kidney. In section
3 we show that DNAM-1 ligands are expressed on rTECs. We detected a role
for DNAM-1 during allospecific T cell priming but not during cytotoxic ac-
tivity against rTECs. Furthermore, we could exclude that ligation of CD155
and CD112 enhances T cell activity during allospecific priming or cytotoxicity
against rTECs. The in vitro results are further strengthened by the finding that
renal allografts deficient in CD155 and CD112 are not protected from rejection.
Summing up, this study gives a deeper insight into the role and relevance of
the CD40 and DNAM-1 pathways during renal allograft rejection and suggests
a new tool to block murine CD40.
Zusammenfassung
Transplantation ist die beste Therapie fu¨r Patienten mit Nierenversagen. Aber
Patienten die ein Transplantat von einem genetisch unterschiedlichen Spender
erhalten tragen ein dauerhaftes Risiko, ihr Transplantat abzustoßen. Die mo-
mentane Strategie, um das zu verhindern, ist eine systemische Immunsup-
pression, welche akute Abstoßungen erfolgreich zu verhindern vermag. Die
verwendeten Medikamente besitzen jedoch toxische Nebenwirkungen und sind
nicht in der Lage chronische Abstoßungen zu verhindern. Weiterhin tragen
diese Patienten aufgrund der Immunsuppression ein erho¨htes Risiko fu¨r In-
fektionen und/oder Krebserkrankungen. Es ist also notwendig, gezieltere und
weniger toxische Therapieoptionen zu finden. Eine weitere Option ist die In-
duktion von immunologischer Toleranz spezifisch fu¨r das transplantierte Organ.
Eine mo¨gliche Strategie, um beide Ziele zu erreichen, ist die Costimulations-
Blockade.
T Zellen beno¨tigen fu¨r eine vollsta¨ndige Aktivierung nicht nur ein Signal durch
den T-Zell-Rezeptor, sondern zusa¨tzlich costimulatorische Signale. Mehrere co-
stimulatorische Signalwege sind inzwischen beschrieben. Sie zu blockieren hat
sich in mehreren Modellen fu¨r Organtransplantation als fo¨rderlich erwiesen.
Doch auch fu¨r die Interaktion zwischen T Zelle und Zielzelle spielt Costi-
mulation eine Rolle. Renale Tubulus-Epithelzellen (rTECs) sind Zielzellen fu¨r
allospezifische zytotoxische T Zellen wa¨hrend der Abstoßung eines Nierentrans-
plantats. Sie exprimieren costimulatorische Moleku¨le unter inflammatorischen
Bedingungen. Ein wichtiger costimulatorischer Signalweg fu¨r beide erwa¨hnten
Vorga¨nge ist der CD40-CD154-Signalweg. Weiterhin wurde DNAM-1 als co-
stimulatorisches Moleku¨l auf T Zellen identifiziert.
In Abschnitt 1 untersuchen wir die Rolle von CD40 auf Spender-Zellen wa¨h-
rend der T Zell Aktivierungs- und Effektorpahse in vitro. Wir zeigen, dass
Donor-CD40 eine Rolle fu¨r die Induktion von Th1, Th17 und zytotoxischen
T Zellen spielt. In einem in vivo-Modell fu¨r Nierentransplantation fanden wir
weiterhin, dass Transplantate von CD40-defizienten Spendern trotz akuter Ab-
stoßung eine bessere Funktion aufweisen. Die meisten Studien, in denen der
CD40-Signalweg bisher blockiert wurde, basierten auf der Nutzung eines An-
tiko¨rpers gegen CD154. Als ein solcher Antiko¨rper zum ersten Mal in Patienten
verwendet wurde, traten jedoch thromboembolische Komplikationen auf, die
eine solche Therapie unmo¨glich machen. In Mausmodellen ist es bisher nicht
mo¨glich gewesen CD40 selbst zu blockieren, da alle verfu¨gbaren Antiko¨rper ago-
nistisch wirken. In Abschnitt 2 zeigen wir daher die Entwicklung eines F(ab)-
Fragments gegen Maus-CD40, das ausschließlich antagonistische Eigenschaften
besitzt. F(ab)86 war in vitro in der Lage CD40-mediierte B Zell Aktivierung
und allospezifische T Zell-Proliferation zu supprimieren. DNAM-1 ist ein cos-
timulatorisches Moleku¨l, das auf T und NK Zellen exprimiert wird. Seine zwei
Liganden CD155 und CD112 werden auf verschiedenen Zelltypen exprimiert,
unter anderem in der Niere. In Abschnitt 3 zeigen wir, dass CD155 und
CD112 auf rTECs exprimiert werden. Wir konnten weiterhin feststellen, dass
DNAM-1 eine Rolle wa¨hrend der allospezifischen T Zell Aktivierung spielt. Fu¨r
die Zytotoxizita¨t gegen rTECs hingegen wird DNAM-1 nicht beno¨tigt. Letzt-
lich konnten wir ausschließen, dass die beiden Liganden CD155 und CD112
einen Einfluss auf allospezifische Aktivierung oder Zytotoxizita¨t gerichtet gegen
rTECs haben. Diese in vitro Ergebnisse konnten wir in einem in vivo-Modell
erha¨rten. Nierentransplantate von CD155- oder CD112-defizienten Spendern
sind nicht vor der Abstoßung geschu¨tzt.
Zusammenfassend ko¨nnen wir mit dieser Arbeit die Rolle von CD40 und DNAM-
1 wa¨hrend der Abstoßung von Nierentransplantaten genauer erkla¨ren und eine
Strategie pra¨sentieren, um murines CD40 zu blockieren.
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Renal transplantation
Renal transplantation is the best therapy option for patients with end-stage
renal disease (ESRD) (Wolfe et al. 1999). Major causes for ESRD are diabetes,
hypertension, and glomerulonephritis (USRDS 2010 Annual Data Report). Di-
abetes and hypertension are both diseases with a high prevalence, especially
in developed countries. The estimated number of diabetes patients all over
the world in the year 2000 was 171 million, with a rising tendency – 366 mil-
lion cases are expected by the year 2030 (Wild et al. 2004). Patients with
diabetic nephropathy develop glomerular hypertrophy and microalbuminuria.
They present with a higher glomerular filtration rate in the beginning, due to
higher intraglomerular capillary pressure. However, eventually the GFR de-
creases because of nodular glomerusclerosis and interstitial injury, which are
most likely exacerbated by hypertension and poor glycemic control (Maric and
Hall 2011).
Also hypertension is a widespread condition with about 972 million patients
all over the world (Hajjar et al. 2006) and a prevalence of 26% (Kearney et
al. 2005). The mechanism how high blood pressure leads to renal damage and
failure is not completely understood. Most probably the damage of the renal
vasculature leads to further damage in the glomeruli, which then lose their abil-
ity to prevent hyperfiltration injury. Furthermore, the glomeruli show signs of
hypoxia (reviewed in Udani et al. 2011).
Glomerulonephritis is a wide definition of several inflammatory diseases affect-
ing the glomeruli including minimal change disease, focal segmental glomerulo-
sclerosis, or membranous glomerulonephritis. IgA nephropathy is the most
common primary glomerulonephritis. This condition is characterized by the
deposition of immune complexes in the kidney. These immune complexes con-
sist of antibodies of the IgA1 subclass, which show a lack of galactose in the
O-linked glycosylations of the hinge region of the heavy chain. Pathologic
complexes of circulating IgG antibodies against these abnormally glycosylated
IgA molecules are very big ( 800 kDa) and deposited in the mesangium of the
glomeruli. Mesangial cells in turn become activated and react by proliferation
and extracellular-matrix deposition. (Reviewed in Suzuki et al. 2011)
Other diseases leading to loss of renal function are for example polycystic kidney
disease and immunologic diseases like lupus nephritis. Polystic kidney disease
is an inherited condition with a prevalence of 1 case in 1’000 population (Torres
et al. 2007). It is characterized by an extensive development of cysts lined by
epithelium, which destroys the renal architecture. The genes affected in autoso-
mal dominant polycystic kidney disease are encoding for PC-1 and PC-2. The
loss of function of one or two of these genes leads to a lack of control in cell
proliferation and apoptosis and a loss of polarity and differentiation of affected
cells. Up to today there are no treatment options for polycystic kidney disease.
(Park et al. 2011)
Systemic lupus erythematosus (SLE) is an autoimmune disease, which can affect
several organs. Involvement of the kidney leads to significant morbidity. The
renal damage in lupus nephritis is mainly caused by the deposition of immune
complexes in the glomeruli, complement activation, and interstitial infiltrates
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of activated lymphocytes (Apostolidis et al. 2011). The prevalence of SLE is
20 to 150 cases per 100’000 population, depending on the region (Tsokos 2011).
The first treatment option for patients with a loss of renal function and no
matching organ donor is dialysis. Generally speaking, in hemodialyisis the pa-
tient’s blood is filtered externally against a dialysis solution across a semiper-
meable membrane, which allows molecules and water to diffuse, but restricts
lager molecules like vitamin B12 and albumin (Hamilton 1999). In peritoneal
dialysis the patient’s peritoneum is used as semipermeable membrane and the
blood in the capillaries is filtered against a dialysis solution, which is infused in
the peritoneal cavity (Khanna and Nolph 1999). Both types of dialysis attempt
to replace renal function by removing metabolic waste products like urea and
creatinine and by diffusion of extrinsic bicarbonate to the patient’s blood in
order to correct metabolic acidosis. However, dialysis is not able to replace
the endocrine functions of the kidney, like production of erythropoietin and
calcitriol (Hamilton 1999). Furthermore, the risk of developing cardiovascular
diseases is much higher in patients on dialysis compared to the normal popu-
lation. The prevalence of cardiac failure is approximately 40 % (Foley et al.
1998). Salt and water overload and anemia in dialysis patients lead to a volume
overload of the left ventricle and in combination with hypertension and arte-
riosclerosis enhance the risk of cardiovascular events (Parfrey and Foley 1999).
Thus, even though dialysis efficiency and safety have been improved over the
years, transplantation is still the best therapy for ESRD – even though early
after transplantation the risk of death is higher compared to patients that stay
on dialysis. However, at 18 months after transplantation the relative risk of
death is as low as 0.32 compared to a dialysis population and the expected
lifespan of the patients increases by 10 years (Wolfe et al. 1999).
Despite these impressive outcome results, patients carrying a renal allograft
are at a constant risk of organ rejection. In order to prevent this, they are
usually treated with a cocktail of immunosuppressive drugs consisting of cor-
ticosteroids, calcineurin inhibitors (cyclosporine A or tacrolimus) and purine
biosynthesis inhibitors (mycophenolate mophetil). With support of these drugs
and induction therapies with T cell-depleting (anti-thymocyte globulin) or -
inhibiting (basiliximab) antibodies, the incidence of acute rejections and early
graft loss was markedly reduced during the last decade. However, chronic rejec-
tion and toxicities of the treatment are still hampering the long term survival
of renal allografts (Fig. 1.1) (Hariharan et al. 2000). Cyclosporine A for ex-
ample has been shown to cause hyperlipidemia, hypertension and new onset
diabetes (Curtis 2002; Guitard et al. 2011; Kobashigawa and Kasiske 1997).
Furthermore, cyclosporine A has a nephrotoxic effect leading to allograft fibro-
sis and reduced renal function (Tedesco and Haragsim 2012). The alternative
calcineurin inhibitor tacrolimus has been shown to be more effective in pre-
venting acute rejection and promoting allograft survival during the first year
compared to cyclosporine A (Webster et al. 2005). However, it shares most
of the side effects with its predecessor (Margreiter 2002; Sperschneider 2001).
Mycophenolate mofetil on the other hand is associated with gastrointestinal
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side effects, which limit tolerability and reduce efficacy due to necessary dose
adjustments (Knoll et al. 2003). Finally, systemic immunosuppression is asso-
ciated with higher rates of infections and cancer possibly leading to death with
a functioning graft (Busnach et al. 2006; Dunn 1990).
A B
Figure 1.1: Development of renal allograft survival 1988 - 1994. Survival of renal
allografts has improved significantly during this time period (A). Long term allograft survival,
however, has not changed markedly (B). Figure adapted from Hariharan et al., 2000
Antigens and antigen presentation
Major histocompatibility antigens
Major histocompatibility complex (MHC) molecules are divided in two major
subclasses - class I and class II. Both groups show a closely related overall
structure with the major feature being the cleft in which peptides derived from
self- and non-self molecules are presented. MHC molecules are essential for the
presentation of antigenic peptides to T cells. MHC class I molecules consist of a
membrane spanning α-chain and a β2-microglobulin. On this complex, which is
expressed ubiquitously on all nucleated cells of the body, peptides derived from
proteasomal degradation are presented to CD8 T cells. MHC class II molecules
are assembled of a non-covalent complex of two transmembrane proteins called
α- and β-chain. This complex is responsible for the presentation of peptides
derived from extracellular proteins to CD4 T cells. MHC class II is expressed
on professional antigen presenting cells (APCs) such as dendritic cells (DCs),
macrophages, and B cells.
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Figure 1.2: Gene structure of the human and murine MHC locus.
Both contain genes for MHC I and MHC II molecules plus additional genes encoding for
accessory molecules. Figure adapted from Janeway’s Immunobiology, 7th edition, 2008
The polygenic MHC is located on chromosome 6 in humans and on chromosome
17 in the mouse. It contains several gene loci for MHC class I and class II
genes. These genes are called human leukocyte antigens (HLA) in humans and
H-2 genes in mice (Fig. 1.2). There are three different MHC class I gene loci
in humans: HLA-A, -B, and -C. The gene loci for MHC class II are called
HLA-DR, -DP, and -DQ. In mice there are three different genes encoding for
MHC class I (H-2K, -D, and -L) and two genes for MHC class II (H-2A, -E).
The gene products of MHC I and II are highly polymorphic. There are more
than 400 alleles of some human MHC class I and class II gene loci and most
human individuals will be heterozygous for them. Expression of the MHC loci
is codominant. Thus, polygeny and polymorphism of the MHC lead to a high
variability of potential peptides presented. This variety is a big evolutionary
advantage concerning the diversity of pathogens a population might encounter.
In transplantation, however, it is one of the major obstacles. This becomes
most evident, when comparing survival of renal allografts from HLA-identical
siblings to those from HLA-non-identical ones. The latter survive significantly
shorter (Colvin and Nickeleit 2006). Furthermore, the outcome of human renal
allografts is dependent on the amount of MHC mismatches in the genes HLA-A,
-B and -DR (Opelz 1997). In mice mutations of one to three amino acids in
single MHC molecules are sufficient to induce allograft rejection (Cornell et al.
2008).
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ABO-antigens
The ABO system discriminates between three blood groups: A, B and O. The
ABO antigens are carbohydrate epitopes present on different core saccharide
chains bound to lipids or proteins. Blood group A is characterized by the ter-
minal trisaccharide GalNacα1-3[Fucα1-2]Galβ, blood group B carries Galαα1-
3[Fucα1-2]Galβ and blood group C Fucα1-2Galβ. ABO antigens are ubiqui-
tously expressed on almost all cells of the body (Szulman 1960). According to
a rule postulated by Karl Landsteiner, humans have antibodies to those ABO
antigens not present in their own body (Landsteiner 1945). In the 1950s and
60s the first attempts to transplant kidneys across the ABO-antigen barrier
(e.g. from an A-donor to an O-recipient) led to hyperacute rejection episodes
within minutes after transplantation (Starzl et al. 1964). Nowadays more and
more kidney transplantations across the ABO-barrier are performed. However,
in this case patients have to undergo a pretreatment attempting to reduce the
amount of circulating antibodies against the antigen to be transplanted. This is
achieved by plasmapheresis, adsorption on protein A or immunoadsorption on
columns with specific carbohydrate antigen epitopes covalently linked to a solid
phase. (Reviewed in Shin and Kim 2011) A phenomenon called accommoda-
tion occurs in many of these patients transplanted in the presence of low levels
of anti-graft antibodies. In this case the A or B antigens are still expressed
on the allograft and de novo produced antibodies bind to them, as shown by
complement fixation in the graft. However, for an unknown reason this does
not lead to allograft injury. Thus, accommodation is defined as the survival of
an allograft in the presence of specific antibodies and complement, which would
otherwise lead to graft rejection. (Reviewed in Dehoux and Gianello 2009)
Minor histocompatibility antigens
Minor histocompatibility antigens are immunogenic peptides derived from poly-
morphic proteins presented in the context of host HLA (Dierselhuis and Goulmy
2009). The role of minor histocompatibility antigen differences has been well
described in the setting of HLA-identical stem cell transplantation (Goulmy et
al. 1996). Differences in minor histocompatibility antigens can also induce renal
allograft rejection in an HLA and blood group matched situation - for example
in HLA-identical sibling donor-recipient-pairs (Dierselhuis and Goulmy 2009).
The most intensively studied group of such antigens is the one encoded on the
Y-chromosome, which is only present in male individuals. HY antigens are in
most cases ubiquitously expressed on renal proximal tubular cells (de Bueger
et al. 1992). In a big multicenter study it was shown, that renal allograft
survival was significantly reduced in women receiving a male organ (Gratwohl
et al. 2008). According to this study the HY-mismatch can lead to acute as
well as chronic rejection. It has furthermore been shown, that de novo anti-
bodies directed against HY antigens correlate with incidence of acute rejection
and plasma cell infiltration (Tan et al. 2008). The influence of other minor
histocompatibility antigens on renal allograft survival is much less studied.
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Ways of allopresentation
Alloreactive T cells can recognize their target in either the indirect, semi-direct,
or direct manner. In indirect allo-recognition, T cells recognize peptides derived
from donor MHC molecules presented on recipient APCs (Shoskes and Wood
1994). The indirect allo-reaction is comparable in strength to any immune re-
action directed against a non-self peptide (Afzali et al. 2008; Womer et al.
2001). It takes place, when recipients APCs take up donor antigen from the
transplanted organ and present it to the cognate T cell in the draining lymph
node. Furthermore, a de novo B cell response is dependent on indirectly al-
loreactive CD4 helper T cells, which recognize peptides derived from antigens
internalized by the B cells and presented in the context of MHC II (Taylor et
al. 2007).
Host APCs can also semi-directly present intact donor MHC molecules, which
they have taken up via cell-cell contact or the incorporation of exosomes (Her-
rera et al. 2004). Directly alloreactive T cells on the other hand recognize in-
tact foreign MHC molecules presented by donor APCs, which migrate from the
transplanted organ to the draining lymph node (so called passenger-leukocytes).
Direct allo-recognition leads to a much stronger response than the indirect
pathway (Liu et al. 1993); also because of a high frequency of directly al-
lospecific T cells, which is estimated to be around 10% of all T cell clones
(Lindahl and Wilson 1977; Sherman and Chattopadhyay 1993). The reason
for this high precursor frequency is still not clear. Two theories arose to ex-
plain this phenomenon. The ”high density determinant”-theory argues, that
directly alloreactive T cells recognize polymorphic epitopes on the donor-MHC
molecules themselves independent of the peptide presented. The ”determinant
frequency”-theory assumes, that the T cell receptors (TCRs) of directly allore-
active T cells recognize a variety of foreign peptides presented on donor-MHC
molecules. In this case the T cell response arises not only against peptides
different in sequence but also to those different in conformation, when bound
to allo-MHC molecules. (reviewed in Archbold et al. 2006) Both mechanisms
do not exclude each other and it is likely, that both take place depending on
the site and magnitude of the structural differences in MHC molecules between
donor and recipient (Afzali et al. 2008).
Renal allograft rejection
The incidence of acute cellular rejection in unsensitized patients is nowadays
5 - 10 % in the first year (Cornell et al. 2008). Pathologically acute rejection
presents with infiltrates of mononuclear cells in the interstitium and inflam-
mation of the tubules and in some cases also the arteries (Colvin and Nickeleit
2006). The interstitial infiltrates consist mostly of CD4 and CD8 T cells (Colvin
and Nickeleit 2006). Another characteristic feature of acute cellular rejection
is the development of tubulitis, an invasion of the tubular epithelium by in-
filtrating T cells and macrophages (Colvin and Nickeleit 2006). A prominent
cytokine found in acutely rejected allografts is IFN-γ, which is secreted by T
helper 1 and cytotoxic CD8 T cells (Hoffmann et al. 2005). Also interleukin
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(IL)-17 has been found in early renal allograft rejection in human urine samples
and an experimental model for acute rejection in the rat (Loong et al. 2002).
Both cytokines are known to activate renal tubular epithelial cells and thereby
induce changes in surface and chemokine expression (Starke et al. 2007; Wolt-
man et al. 2000). In experimental studies it has been shown, that the T cells
responsible for acute rejections are mostly directly alloreactive (Benichou et al.
1999).
Also B cell-dependent mechanisms can lead to allograft rejection. Hyperacute
rejection is mediated by preformed antibodies against antigens expressed on the
allograft. It is a strong immune response leading to graft loss already minutes to
hours after transplantation. This complication is mostly avoided by HLA- and
blood group-matching and pretransplant cytotoxic crossmatch testing (Bohmig
et al. 2002). However, approximately 25% of acute rejections are at least in
part due to a humoral component (Cornell et al. 2008). Acute humoral rejec-
tion can occur days to weeks or years after transplantation. Pathologically it
is recognizable by detection of deposits of C4d in the peritubular capillaries.
C4d is an inactive fragment of C4b, a part of the classic complement pathway.
It has no known function itself but remains bound in the tissue for several
days after complement activation by specifically bound antibodies. (Reviewed
in (Cornell et al. 2008)) Even though 88 − 95% of patients presenting with
C4d deposits have anti donor-HLA antibodies (Colvin 2007), these are not nec-
essarily detectable in the circulation – probably due to the absorption of the
alloantibodies by the graft (Martin et al. 2005).
Chronic allograft rejection can be cellular or humoral or both (Cornell et al.
2008). Pathologic features of chronic renal allograft rejection are chronic changes
such as transplant glomerulopathy, peritubular capillaropathy, transplant arte-
riopathy, interstitial fibrosis, and tubular atrophy (Colvin and Nickeleit 2006).
Experimental studies have suggested that T cells mediating chronic rejection
are mostly activated by the indirect pathway (Benichou et al. 1999).
Costimulation and Coinhibition
Three signals are necessary for T cell activation
Antigen presenting cells deliver more than one signal to T cells in order to acti-
vate them. At least three signals are needed to achieve a fully functional T cell.
Signal one is delivered by the interaction of the TCR with its cognate antigen
presented in the context of self-MHC. In the case of direct allo-recognition this
signal can also be delivered by a foreign MHC molecule, as discussed above.
The additional binding of CD4 to MHC class II and CD8 to MHC class I,
respectively, is necessary, but not sufficient to induce T cell activation and pro-
liferation. Signal 1 leads to the activation of phospholipase C-γ (PLC-γ). PLC-
γ in turn cleaves phosphatidylinositol bisphosphate (PIP2) into diacylglycerol
(DAG) and inositol triphosphate (IP3). DAG leads to activation of kinases like
protein kinase C (PKC), which lead to activation of the transcription factors nu-
clear factor κB (NFκB) (Cheng et al. 2011) and via the Ras-mitogen activated
protein kinase (MAPK) cascade AP-1. IP3 increases the intracellular Ca
2+
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concentration. This activates a serine phosphatase called calcineurin, which in
turn activates a third transcription factor named nuclear factor of activated T
cells (NFAT), which can only enter the nucleus in a dephosphorylated state.
These three transcription factors bind to the promoter region of the IL-2 gene
and are essential for its transcription. IL-2 is an essential autocrine cytokine for
the survival of activated T cells. However, a signal 2 (a so called co-stimulatory
signal) is needed to increase IL-2 signaling. This signal is for example delivered
by the costimulatory receptor CD28 expressed on the T cell. CD28 is the best
characterized and probably most important costimulatory receptor and binds
to B7-1 (CD80) or B7-2 (CD86) presented by the APC. The triggering of CD28
leads to an increase in the nuclear translocation of AP-1 and NFκB, which en-
hances the initiation of transcription of IL-2. Furthermore, the stability of IL-2
mRNA is increased. Both effects lead to a much higher IL-2 protein production
(signal 3). Naive T cells express a receptor for IL-2 consisting of a β- and a
γ-chain. This receptor binds IL-2 only with a moderate affinity. The delivery
of a costimulatory signal also induces the expression of the α-chain, which gives
the IL-2 receptor a high affinity for its ligand.
Costimulatory pathways
In addition to CD28-B7 there is a variety of costimulatory receptor-ligand pairs
described (summarized in Fig. 1.3). A further costimulatory receptor is in-
ducible costimulator (ICOS, CD287) which binds to ICOS-ligand (ICOS-L).
ICOS-L is expressed on activated DCs, monocytes and B cells. ICOS does not
induce IL-2 production, but regulates the expression of other cytokines pro-
duced by CD4 subsets like IFN-γ, TNF-α, IL-4, IL-5, and IL-10 (Hutloff et
al. 1999). Mice deficient in ICOS are not capable to control viral or worm
infections owing to impaired Th1 and Th2 responses, respectively (Kopf et al.
2000). ICOS-ICOS-L interaction also plays a role in the development of follic-
ular T helper cells and their interaction with B cells. Mice lacking ICOS show
impaired germinal center formation and antibody class switching (reviewed in
Simpson et al. 2010).
CD27 belongs to the TNF-receptor family and is constitutively expressed on
naive T cells. It binds to CD70 on DCs and gives a strong co-stimulatory
signal early in the activation process. CD27 signaling supports T cell survival
rather than the entry into the cell cycle (reviewed in Denoeud and Moser 2011).
4-1BB (CD137) and 4-1BBL (CD137 ligand) is another pair of the TNF-receptor
and -ligand family. 4-1BBL is expressed on activated DCs, macrophages and B
cells. The interaction of these two molecules is bidirectional and delivers acti-
vating signals to both the T cell and the APC (reviewed in Shao and Schwarz
2011).
OX40 and OX40L also belong to the TNF-receptor/TNF-ligand family. OX40 is
expressed on activated T cells (Gramaglia et al. 1998). Its ligand is expressed
on activated DCs, B cells and vascular epithelial cells (Stuber and Strober
1996). Their interaction plays a critical role in Th1/Th2 differentiation as well
as memory T cell generation (Lane 2000; Rogers et al. 2001). Furthermore,
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OX40 is constitutively expressed on regulatory T cells (Treg). In these cells
OX40 ligation leads to decreased FoxP3 expression and loss of suppressor func-
tion (Vu et al. 2007).
The receptor-ligand pair CD40-CD154 (CD40L) will be described in more de-
tail in the following section of this chapter.
If a T cell receives signal 1 in the absence of signal 2, for example via CD28,
it either undergoes apoptosis or reaches a state of anergy. Anergy is defined
as a state in which the T cell is not able to be activated anymore, even if it
receives signal one in combination with co-stimulation at a later time point.
This process is important to maintain self-tolerance. If a T cell was activated
without a costimulatory signal, auto-reactive T cells would be easily activated
in the periphery by different kinds of cells.
Coinhibitory pathways
Another way of controlling a T cell response is the ligation of coinhibitory
receptors, such as cytotoxic T lymphocyte antigen 4 (CTLA-4, CD152) or pro-
grammed cell death-1 (PD-1). CTLA-4, an additional receptor for the B7
molecules, is induced on activated T cells. It binds B7-1 and B7-2 with a twenty
times higher avidity than CD28. Thus, CTLA-4 reduces binding of CD28 to its
ligands and deliverers an inhibitory signal to the T cell itself. This leads to a re-
duced production of IL-2 and subsequently to less T cell proliferation (Walunas
et al. 1996). Mice lacking CTLA-4 develop a multiorgan disease characterized
by a strong overgrowth of lymphocytes (Tivol et al. 1995; Waterhouse et al.
1995).
PD-1 is induced transiently on activated T cells. One of its two ligands PD-L1
(B7-H1) is expressed on a wide variety of cells including T cells, B cells, DCs,
and macrophages but also on nonhematopoetic cells like vascular endothelial
cells or renal tubular epithelial cells (Fife and Pauken 2011). The other lig-
and PD-L2 (B7-DC) is induced on APCs during inflammation. PD-1/PD-L1
interactions have been shown to play a role in regulating autoreactive T cells
specific for tissue-restricted self-antigens (Fife and Pauken 2011). PD-1/PD-L2
interactions in contrast are critically involved in regulating immune responses
to environmental antigens (Fife and Pauken 2011). Mice lacking PD-1 develop
autoimmune diseases, because they lack the ability to regulate T cell activation
(Nishimura et al. 1998; Nishimura et al. 1999; Nishimura et al. 2001). Re-
cently, it has been shown that the B7-1 molecule expressed on the surface of T
cells serves also as receptor for PD-L1 and thus also transmits negative signals
to T cells (Butte et al. 2007). This suggests that PD-1 might not be the unique
mediator of negative signals delivered by PD-L1.
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Figure 1.3: Costimulatory and -inhibitory molecules. T cells need additional signals
to the one mediated by the T cell receptor in order to be fully activated. A secondary
signal can be given via costimulatory receptors. Here a variety of these molecules expressed
on the T cell and their respective ligands expressed on the APC are depicted (receptors in
blue, ligands in green). Furthermore, there are receptors that negatively regulate the T cell
response (red). The depicted receptors either belong to the Immunoglobulin (Ig)- or the
TNF-receptor-superfamily. The ligands on the other hand either belong to the Ig- or the
TNF-receptor-ligand-superfamily.
T helper cell differentiation
CD4 positive T helper (Th) cells can differentiate into different subsets. In
order to do so they need a third signal from the APC. Signal 3 is delivered by
cytokines that drive the T cell to one or the other direction. T helper subsets
are defined by a characteristic transcription factor and specific set of cytokines
secreted (summarized in Fig. 1.4). The first two T helper cell subsets described
are Th1 and Th2. Th1 cells are characterized by the transcription factor T-
bet. They produce IL-2 and IFN-γ. For their induction they require IL-12 and
IFN-γ as signal 3. This Th subset plays a major role in the clearance of acute
infections. Furthermore, it is involved in acute allograft rejection (D’Elios et al.
1997). The specific transcription factor for Th2 cells is GATA-3. These cells
require IL-4 as third signal and secrete mainly IL-4 and IL-5. Their importance
has been shown in chronic immune reactions like allergy. In allograft rejection
this Th subset plays a role rather in chronic rejection (Shirwan 1999). A subset
of Th cells discovered in 1995 are the regulatory T cells (Treg) (Sakaguchi et al.
1995). Treg are characterized by the expression of FoxP3 and their secretion of
inhibitory cytokines like TGF-β and IL-10. Treg are essential for regulating im-
mune responses, which is important to keep self tolerance during strong immune
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responses to pathogens. Treg need TGF-β as signal 3. TGF-β, however, can
also induce another subset of Th cells. If it is secreted simultaneously with IL-6
this rather drives the development of Th17 cells. This Th subset has recently
been described (Langrish et al. 2005; Park et al. 2005) and is characterized by
its transcription factor RORγT. Th17 cells produce proinflammatory cytokines
like IL-6 and IL-17. Their role in different immune responses is not completely
explored yet. They have been shown to be important during infection with
extra- and intracellular bacterial pathogens (Raffatellu et al. 2008; Ye et al.
2001) but also in models for autoimmune diseases like experimental autoim-
mune encephalomyelitis (EAE) or rheumatoid arthritis (reviewed in (Hu et al.
2010)). The role of Th17 cells in allograft rejection is not yet clear and subject
of investigations.
Taken together, signal 1 delivered by the TCR is essential for activation, signal
2 delivered by costimulatory receptors for survival, and signal 3 delivered by
the cytokine milieu for the differentiation of a T cell.
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Th1 protection against intracellular
pathogens, autoimmunity, 
acute rejection
IL-12
FoxP3 Treg
IL-10 immune suppressionTGF-β
RORγT Th17
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Figure 1.4: Th subsets. Upon interaction with an APC presenting the cognate antigen and
providing costimulation, the naive CD4 T cell is driven to one of the indicated Th subtypes
through the cytokines provided by the APC. The characteristic transcription factors, cytokine
profiles, and roles of the Th subsets are indicated.
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The CD40-CD154 pathway
CD40
CD40 is a costimulatory receptor belonging to the TNF-receptor (TNF-R) fam-
ily. It is a type I transmembrane protein consisting of 277 and 305 amino acids
in human and mouse, respectively. The intracellular domain does not show a
close relationship to any other characterized molecule. The extracellular do-
main is homologous to other TNF-receptor family molecules. It contains three
cysteine rich domains, of which each has 2 - 3 disulfide bridges (An et al. 2011).
Human and murine CD40 share 62% amino acid identity. All 22 cystein residues
are conserved between the two species indicating, that both CD40 molecules
fold into the same protein domains (van Kooten and Banchereau 2000). The
gene for CD40 is encoded on chromosome 20 in humans and on chromosome 2
in mice (van Kooten and Banchereau 2000). CD40 is expressed on B cells and
DCs, monocytes, platelets, and macrophages. In addition it is also expressed
on non-hematopoetic cells such as fibroblasts, epithelial, and endothelial cells
(Banchereau et al. 1995; Bourgeois et al. 2002; van Kooten and Banchereau
1997).
Trimerization of the CD40 receptor leads to recruitment of TNF-R-associated
factors (TRAFs) to the cytoplasmic domain of CD40. There are six known
TRAFs so far, which can induce different signaling pathways including the
canonical and non-canonical NFκB-pathways, the MAPKs, phosphoinositide 3-
kinase (PI3K), as well as the PLCγ pathway (Bishop et al. 2007). All TRAFs
except for TRAF4 have been shown to interact with CD40 either directly or
indirectly via other TRAFs (Elgueta et al. 2009). Also TRAF-independent
signaling via the Janus family kinase (Jak3), which can bind to the cytoplasmic
domain of CD40 directly, takes place. This pathway induces the phosphoryla-
tion of signal transducer and activator of transcription 5 (STAT5) (Saemann et
al. 2003; Saemann et al. 2002).
The biological consequences of CD40 ligation differ greatly depending on the
cell type it is expressed on. Some of these are summarized in table 1.1 (mod-
ified from van Kooten and Banchereau 2000). In B cells CD40 induces prolif-
eration, differentiation and antibody production. It has been shown in vitro
that CD40 activation has a direct effect on cytokine production (IL-6, IL-10,
TNF-α, lymphotoxin-α) and surface molecule expression (intercellular adhe-
sion molecule-1 (ICAM-1), CD23, B7-1, B7-2). Furthermore, MHC class I and
II are upregulated together with the TAP transporter, which is an important
part of the pathway for peptide loading on MHC class I (Khanna et al. 1997).
Thereby the ability of the B cell to present antigen on MHC and activate T
cells is enhanced after CD40 triggering. Furthermore, CD40 ligation is essential
for the initiation of isotype switching and somatic hypermutation to enhance
antibody affinity in germinal center B cells (Elgueta et al. 2009). The cytokine
milieu determines the type of antibody produced afterwards. In humans IL-4
and IL-13 induce the switch from IgM to IgE and IgG4. Switch to IgG1 and
IgG3 is induced by IL-10 and the determining factor for IgG2 is yet to be found.
The switch to IgA is promoted by a combination of IL-10 and TGF-β. These
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important functions of the CD40-CD154 pathway are lost in patients with the
X-linked immunodeficiency hyper-IgM syndrome. These patients show a ge-
netic alteration of the CD154 gene (Notarangelo et al. 1996). They are not
able to mount proper T cell-dependent antibody responses or to develop B cell
memory, and they have only little circulating class-switched antibodies. This
phenotype was reproduced in mice by knocking out the gene for CD40 or CD154
(Kawabe et al. 1994; Renshaw et al. 1994; Xu et al. 1994).
CD40 is also expressed on monocytes and DCs, both professional APCs. CD40
ligation on these cells results in enhanced survival, the secretion of cytokines
and enzymes, enhanced monocyte tumoricidal activity, and nitric oxygen syn-
thesis. Furthermore, other costimulatory molecules like ICAM-1, LFA-3, B7-1,
and B7-2 are upregulated. Activation of CD40 on DCs also enhances their abil-
ity to cross-present antigen (Quezada et al. 2004). Therefore CD40 signaling
is one of the critical signals for complete DC maturation, driving them to be
the most potent APCs (Banchereau and Steinman 1998). The interaction of
DCs and CD4 T cells via the CD40-CD154 pathway has been shown to enable
the DC to effectively stimulate cytotoxic CD8 T cell responses (Bennett et al.
1998; Schoenberger et al. 1998). In a mouse model it has furthermore been
shown, that the interaction of CD154 on CD8 T cells with CD40 on DCs is
necessary to stimulate maximal responses in the absence of CD4 help (Her-
nandez et al. 2007). Along with this, mice lacking CD154 mount reduced T
cell responses to both intra-and extracellular pathogens (Campbell et al. 1996;
Soong et al. 1996; Wiley and Harmsen 1995). Some pathogens however deliver
other signals (like toll-like receptor (TLR)-signals), which may substitute for
the CD40-CD154 crosstalk between DC and CD4 T cell and enable the DC to
activate CD8 T cells efficiently (Hamilton et al. 2001). This is consistent with
the observation, that CD154 deficient mice can mount normal T cell responses
to different viruses (Oxenius et al. 1996; Whitmire et al. 1996).
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Table 1.1: Differential effects of CD40 activation on several cell types
Cell type Functional consequences
Pre-B cells proliferation
CD23 expression
Naive mature B cells proliferation
differentiation
isotype switch
Germinal center B cells proliferation
differentiation
Fas expression
selection
Plasma cells IL-6 production
Monocytes/macrophages cytokine secretion
NO production
production of metalloproteinases
monocyte procoagulant activity
tissue factor expression
Dendritic cells growth and survival
expression of costimulatory molecules
enhanced cytokine production
Langerhans cells see dendritic cells
T cells proliferation
CD25 expression
cytokine production
Endothelial cells up-regulation of CD54, CD62E, CD106
(HUVEC) increased tissue factor/thrombomodulin expression,
and proagulant activity
T cell costimulation
increased production of LIF, IL-6, GM-CSF
Thymic epithelial cells GM-CSF production
Kidney epithelial cells cytokine/chemokine secretion:
IL-6, LIF, GM-CSF, IL-8, MCP-1, RANTES
Introduction 24
CD154
CD154, the ligand of CD40, is a type II transmembrane protein with its C-
terminus on the extracellular side of the cell membrane. The extracellular
domain contains a TNF-like domain, whose three dimensional organization re-
sembles the one of TNF-α and is responsible for the formation of the active
homotrimeric form of the molecule (Karpusas et al. 1995). Human and murine
CD154 share 78% amino acid identity. The gene for CD154 is located on the
X chromosome. CD154 is expressed primarily on activated T cells, but also
on activated B cells and platelets. Under inflammatory conditions CD154 ex-
pression can also be induced on monocytic cells, natural killer (NK) cells, mast
cells, and basophils (Carbone et al. 1997). CD154 is also secreted in a soluble
form, which shows similar activities as the membrane bound form (Graf et al.
1995; Mazzei et al. 1995).
CD154 is not only the ligand for CD40, it can also act as signal transducing re-
ceptor itself. Van Essen et al. showed that the interaction between B cells and
T cells mediated through CD40 and CD154 is bidirectional, enabling T cells to
deliver effective help to B cells and allowing B cells to respond to it (van Essen
et al. 1995). CD154 signaling pathways are not completely elucidated yet. So
far it is known, that CD154 activation leads to phosphorylation of PLCγ and
a subsequent calcium release and PKC activation (Brenner et al. 1997). This
process is abrogated by calcineurin inhibition (Blair et al. 2000). Another sig-
nal, whose consequences are not clear, conducted by CD154 is the activation of
a neutral sphingomyelinase resulting in ceramide production (Koppenhoefer et
al. 1997). The biological effects of this signaling pathway are not extensively
studied. Studies using an approach for activating T cells in the absence of autol-
ogous APCs, like DCs or B cells, providing costimulation and cytokines brought
some insight, but are still controversial. Cayabyab et al. showed that human
T cells stimulated with anti-CD3 antibodies and cocultured with a murine cell
line expressing human CD40 proliferate, produce IFN-γ and IL-2. These T cells
were also able to acquire cytotoxic activity (Cayabyab et al. 1994). In simi-
lar experiments Blair et al. showed that resting human CD4 T cells stimulated
with antibodies against CD3 and CD154 proliferate for a short time and secrete
IFN-γ, TNF-α, and IL-10 but not IL-2 (Blair et al. 2000). These results were
confirmed using a murine cell line expressing CD40 instead of an anti-CD154
antibody (Blair et al. 2000).
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CD40-CD154 blockade in autoimmunity and trans-
plantation
CD40-CD154 crosstalk plays a central role in B and T cell priming and activa-
tion. Therefore it is an attractive target to block in different disease models.
Especially in autoimmunity and transplantation, promising results have been
obtained. An overview over the published antibodies against murine and human
CD154 and CD40 is given in tables 1.2 and 1.3.
Table 1.2: Antibodies directed against murine CD154 and CD40
Name Molecular
characteristics
Mechanism Used in
directed against murine CD154
MR1 Hamster IgG3 Costimulatory
blockade
murine models for
tolerance induction in
combination with CD28
pathway blockade,
DST, bone marrow
transplantation
directed against murine CD40
FGK4.5 Rat IgG2a activating e.g. induction of im-
mune responses against
tumors (Turner et al.
2001)
3/23 Rat IgG2a activating
HM40-3 Hamster IgM activating
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CD40-CD154 blockade in autoimmunity
Multiple sclerosis is a mainly Th1-mediated autoimmune demyelinating disease
of the central nervous system. The CD40-CD154 pathway has been shown to be
involved in MS-lesions (Gerritse et al. 1996). In models for murine experimen-
tal autoimmune encephalomyelitis (EAE), use of a blocking antibody against
CD154 could ameliorate disease and even later after treatment prevent disease
relapses (Gerritse et al. 1996; Howard et al. 2002). This was also proven in
nonhuman primates: Using a murine antibody blocking CD40 or its chimeric
form, EAE could be reduced and even after onset the formation of new lesions
could be avoided (Laman et al. 2002; t Hart et al. 2005). Zheng et al. showed
reduced autoimmune arthritis in mice treated with an siRNA against CD40
(Zheng et al. 2010). Finally, in a murine model for SLE administration of an
anti-CD154 antibody early in life could delay onset of disease (Mohan et al.
1995). And when combining CD154- with CD28-blockade in this setting, onset
of lupus nephritis could be delayed for months (Daikh et al. 1997).
CD40-CD154 blockade as immunosuppression in transplantation
The importance of the CD40-CD154 pathway has also been studied in allore-
activity: CD154 deficient T cells fail to induce graft-versus-host disease, when
injected into F1 recipients (Buhlmann and Noelle 1996). Furthermore, the re-
jection of allogeneic cells injected into CD154 knock-out animals is impaired
(Shepherd and Kerkvliet 1999). CD154 deficient recipients of cardiac allografts
show long term allograft survival and donor-specific tolerance (Shimizu et al.
2000). Finally, the CD40 pathway has been shown to be more critical for in-
duction of cardiac allograft rejection than the CD28 pathway (Bingaman et
al. 2001). Despite the beneficial effect of CD154 deficiency on acute rejection,
chronic rejection still occurs (Shimizu et al. 2000).
However, blockade of the CD40-pathway alone is not sufficient to induce stable
tolerance to allografts. The survival of cardiac or islet allografts is prolonged,
when CD40 is blocked at the time of transplantation (Larsen et al. 1996;
Parker et al. 1995). But eventually all allografts in these studies were rejected.
However, if CD40-CD154 blockade is combined with the blockade of the CD28
costimulatory pathway, murine cardiac allografts survive long term without
signs of rejection (Larsen et al. 1996). Interestingly, addition of cyclosporin
A to this protocol prevents allospecific tolerance, indicating that T cells need
to receive signal 1 via the TCR in order to be tolerized (Larsen et al. 1996).
This mechanism has been shown to be true also for the induction of anergy
in human T cells in vitro (Koenen et al. 2005). The combination of blockade
of both costimulatory pathways (CD40 and CD28) was successfully translated
into non-human primate models for renal and islet transplantation (Adams et
al. 2005; Kirk et al. 1997).
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Tolerance induction by donor-specific transfusion
Several strategies to induce donor-specific tolerance are under investigation in
murine and non-human primate models. Most of them rely on blockade of the
CD40-CD154 pathway. One strategy to induce donor specific tolerance is the
combination of donor-specific transfusion (DST) in combination with CD40-
CD154 pathway blockade by antibodies. DST can consist of donor blood or
splenocytes (Markees et al. 1998; Zheng et al. 1999). This strategy has been
shown to efficiently prolong allograft survival in murine models for islet, heart
and airway allografts (Chalermskulrat et al. 2006; Zheng et al. 1999). For long
term skin graft survival DST under CD154 blockade is only sufficient, when the
recipients are thymectomized (Markees et al. 1998; Phillips et al. 2003). Mech-
anistical studies have shown that both T cell subsets (CD8 and CD4) contribute
to allospecific tolerance induced in this way and that especially indirectly allore-
active T cells are rendered hyporesponsive (Gao et al. 2004; Kishimoto et al.
2004; Phillips et al. 2006). Furthermore, a CD4 dependent deletion of directly
alloreactive CD8 T cells has been observed (Iwakoshi et al. 2000). Finally,
a similar protocol showed efficacy in preventing renal allograft rejection in a
non-human primate model. Recipients were treated with DST under CD154
blockade (for eight weeks) combined with an mTOR-inhibitor (sirolimus, for
three months). Three out of five animals receiving the triple therapy survived
rejection-free for more than 500 days after therapy withdrawal and remained
tolerant even after a secondary donor-specific skin graft challenge (Preston et
al. 2005). Interestingly, TLR-signaling prevents tolerance induction achieved
by CD40-CD154 blockade and DST. When TLR agonists are administered si-
multaneously with the tolerogenic treatment, B7-molecles are upregulated on
transfused APCs and no tolerance is achieved (Thornley et al. 2006).
Tolerance induction by mixed chimerism
Another way to achieve donor-specific tolerance is the induction of mixed chi-
merism. The basis for this is the observation made by Owen in dizygotic bovine
twins, in which due to anastamoses of placental vessels both individuals had red
blood cells from the other circulating in the bloodstream (Owen 1945). These
animals were tolerant to skin grafts from the respective twin but not to those
from siblings of separate birth (Billingham and Reynolds 1952). This state was
thought to be due to the permanent engraftment of precursor cells that were
exchanged during fetal development, a time at which the immature immune
system is not capable of rejection yet. This could be proven by performing
in utero transplantation of donor-type cell mixtures in chicken, rabbits, and
mice (Billingham et al. 1953; Billingham et al. 1955). Thus, the principle
of tolerance achieved by mixed chimerism differs from the strategies mentioned
above. In this case tolerance relies on a central deletion of alloreactive T cells by
donor bone marrow derived DCs that engraft in the thymus. This principle was
translated to an induction of mixed hematopoetic chimerism in adult animals
with an established immune system applying a myeloablative irradiation and
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subsequent host and donor-derived bone marrow transplantation (Main and
Prehn 1955; Ildstad and Sachs 1984). The protocols have been improved since
then. The conditioning was reduced to a non-myeloablative, sparing enough of
the host bone marrow to allow survival also without subsequent bone marrow
transplantation (Sharabi et al. 1992). Now it is known that in mice a minimal
treatment including 3 Gy total body irradiation and a single dose of a blocking
anti-CD154 antibody is sufficient to induce a stable mixed chimerism (Fehr et
al. 2005; Takeuchi et al. 2004; Wekerle et al. 1999). Induction of mixed
chimerism has been shown to lead to indefinite survival of skin, islet, lung, or
cardiac allografts in murine models (Guo et al. 2008; Li et al. 2008; Seung et al.
2000). A similar protocol could also be translated to non-human primates and
long term renal allograft tolerance was achieved in five out of eight recipients
(Kawai et al. 2004). Also a small series of patients underwent treatment for
mixed chimersim induction combined with renal transplantation. Four of five
patients accepted their kidney allograft (Kawai et al. 2008).
DNAX accessory molecule-1 and its ligands
DNAX accessory molecule-1
DNAX accessory molecule-1 (DNAM-1, CD226) was first described in 1996 as
a novel adhesion molecule involved in the cytolytic function of T lymphocytes
(Shibuya et al. 1996). DNAM-1 belongs to the immunoglobulin superfamily
and its sequence shows similarity with CD96 (TACTILE) (Shibuya et al. 1996).
DNAM-1 is expressed on all T cell subsets including γδT cells, NK cells, mono-
cytes and on a subset of B cells (Shibuya et al. 1996). Later DNAM-1 was
shown to be identical to a membrane protein described earlier on platelets and
called PTA1 (Kojima et al. 2003; Scott et al. 1989).
DNAM-1 plays a role in several processes in the immune system, which are
described in the following paragraphs:
1. T cell priming
2. Cytotoxic T cell activity against tumor cells and non-professional APCs
3. Cytotoxic activity of NK cells against tumor cells and DCs
4. Extravasation of monocytes across the endothelial barrier
5. Platelet adhesion to endothelial cells
The accessory molecule lymphocyte function-associated antigen 1 (LFA-1) has
been shown to not only be important for lymphocyte adhesion, but also dur-
ing priming of naive T cells. The interaction of LFA-1 and its ligand ICAM-1
(CD54) expressed on the antigen presenting cell allows to keep the cell-cell con-
tact long enough for the T cell to recognize its cognate antigen. If the TCR
binds to a matching MHC-peptide complex, LFA-1 affinity to ICAM-1 is in-
creased to further prolong T cell-APC contact. It has been shown, that the
activation of naive human T cells with an antibody against CD3 and one ac-
tivating LFA-1 leads to T cell proliferation and Th1 induction (Shibuya et al.
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2003). The phosphorylation of DNAM-1 at tyrosine 322 is essential for this
process (Shibuya et al. 2003).
DNAM-1 on NK and cytoxic T lymphocytes (CTLs) also plays a role in rejec-
tion of tumor cells expressing DNAM-1 ligands as shown in DNAM-1 deficient
mice (Gilfillan et al. 2008; Iguchi-Manaka et al. 2008). Apart from this defect
DNAM-1 deficient mice show a normal composition of lymphocyte populations
in the spleen, bone marrow, and lymph nodes (Gilfillan et al. 2008; Iguchi-
Manaka et al. 2008). Ectopic expression of DNAM-1 ligands can increase NK
mediated cytotoxicity against tumor cell lines (Tahara-Hanaoka et al. 2004).
The same is true for CD8 T cell proliferation in response to non-professional
APCs like B cells pulsed with antigen (Gilfillan et al. 2008). Whereas the
activation of CD8 T cells by professional APCs does not seem to be dependent
on DNAM-1 (Gilfillan et al. 2008), cytolytic activity of NK cell against DCs is
(Pende et al. 2006).
DNAM-1 has two known ligands: CD155 (Necl-5, Tage4, PVR) and CD112
(Nectin-2, Prr2, HVEB) (see Fig.1.5) (Bottino et al. 2003; Tahara-Hanaoka et
al. 2004). Both molecules have been shown to be expressed on endothelial cells
(Reymond et al. 2004). The interaction between CD155 and DNAM-1 is crucial
for the transmigration of human monocytes across an endothelial monolayer,
as the process of trans-endothelial migration is blocked in the diapedesis phase
when DNAM-1 is blocked (Reymond et al. 2004). Furthermore, the activation
of human CD8 T cells by endothelial cells has been shown to be partially in-
fluenced by DNAM-1/CD155 interaction. Interestingly, CD8 T cells proliferate
similarly but produce more IFN-γ, when CD155 or DNAM-1 is blocked (Es-
calante et al. 2011). Expression of CD155 on endothelial cells has been shown
to be important for platelet adhesion to endothelial cells. Thrombin-activated
platelets show phosphorylation of DNAM-1 at tyrosine 322 and blockade of
DNAM-1 with an antibody reduces adhesion of platelets to human endothelial
cells (Kojima et al. 2003). Finally, blockade of DNAM-1 leads to amelioration
of CD8 T cell mediated graft-versus-host-disease in a murine model (Nabekura
et al. 2010).
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DNAM-1
CD96
CD155
CD112
non-professional APCT cell
TCR
MHC I
Figure 1.5: Schematic illustration of the interactions between a T cell and a non-
professional APC. The T cell recognizes its cognate antigen in the context of MHC with its
T cell receptor (TCR). For further activation the T cell needs further costimulatory signals,
which can be delivered via DNAM-1 ligation by its two ligands CD155 and CD112 expressed
on the non-professional APC. CD155 has another receptor called CD96.
DNAM-1 ligands
The two ligands for DNAM-1, CD112 (nectin-2) and CD155 (necl-5), belong to
the nectin- and nectin-like (necl) family of cell adhesion molecules, respectively.
The family consists of nectin-1 to -4 as well as necl-1 to -5. These molecules
are immunoglobulin-like adhesion molecules, with three immunoglobulin-like
loops in the extracellular region, a transmembrane segment and a cytoplasmic
tail. Nectin or necl proteins are able to bind nectins of the same or different
types on the adjacent cell surface after forming a homodimer in cis. In general
heterophilic trans-interactions are stronger then homophilic trans-interactions
(Satoh-Horikawa et al. 2000). Nectins initiate the formation of adherence junc-
tions between epithelial, endothelial, or fibroblast cells, before cadherins are
involved (Takai et al. 2003).
CD112 acts as entry-receptor for α-herpesvirus and is expressed on endothelial
and epithelial cells in various organs, in mouse especially in liver and kidney
(Bottino et al. 2003; Nabekura et al. 2010; Takai et al. 2008). CD112 ex-
pression has also been shown to be pronounced on cells lining high endothelial
venules in human lymph nodes (Pende et al. 2006). Furthermore, expression
on human monocyte-derived DCs has been shown (Pende et al. 2006). CD112
knock-out mice show no obvious phenotype apart from male infertility due to
defects in nuclear and cytoskeletal morphology and mitochondrial localization
in spermatozoa (Bouchard et al. 2000; Mueller et al. 2003).
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The second ligand for DNAM-1, CD155, has a higher affinity to DNAM-1 than
CD112 (Reymond et al. 2004; Seth et al. 2009). CD155 acts as receptor for
poliovirus (Takai et al. 2008). It is also expressed on various epithelial and en-
dothelial cell types and APCs (Gilfillan et al. 2008). In the mouse it has been
localized mostly to liver, heart, and kidney (Nabekura et al. 2010). CD155
has been shown to play a major role in cell movement and is essential for the
formation of leading-edge structures (Takai et al. 2008). Furthermore, endo-
cytosis of CD155 upon newly formed cell-cell contact after movement leads to
a signaling pathway that inhibits further movement and proliferation (Takai et
al. 2008). CD155 is upregulated in different types of cancer cells, and this is
correlated with enhanced metastasis (Ikeda et al. 2004; Morimoto et al. 2008).
In contrast to most of the other nectin and necl molecules CD155 is not able
to build homodimers in trans (Takai et al. 2008). CD155 knock-out mice do
not show an overt phenotype and display normal cell distribution in most lym-
phatic organs (Maier et al. 2007). However, these mice show a reduced number
of CD8 single positive T cells in the thymus and a reduced ability to mount
humoral immune responses to orally administered antigens (Maier et al. 2007;
Qiu et al. 2010).
CD155 binds to a second receptor CD96 (tactile), which is expressed on T and
NK cells but not on the majority of B cells, monocytes and granulocytes (Meyer
et al. 2009). Their interaction has been shown to promote NK mediated killing
of tumor cells (Fuchs et al. 2004). CD96 is upregulated on T cells late after
activation (six to nine days) (Meyer et al. 2009; Wang et al. 1992). CD96 ex-
pression has furthermore been found in a variety of adult human tissues (Meyer
et al. 2009). Disruption of the CD96 gene has been linked to manifestation
of the C syndrome (Opitz Trigonocephaly), indicating a role for CD96 in de-
velopmental processes in addition to its immunologic function (Kaname et al.
2007).
Renal tubular epithelial cells as non-professional APCs
Renal tubular epithelial cells (rTECs) are the cells lining the tubulus. They
have the important task to reabsorb water and ions from and secrete waste prod-
ucts into the primary urine formed in the glomerulus. Thereby they maintain
mineral ion homeostasis and water balance. Apart from that rTECs also exe-
cute an immunomodulatory function by expression of certain surface molecules
and secretion of chemo- and cytokines. Under inflammatory conditions rTECs
upregulate MHC class I and II molecules (Wuthrich et al. 1990). They also
express the costimulatory molecules CD40 and ICOS-L (Starke et al. 2007).
However, the two ligands for the major costimulatory receptor CD28 B7-1 and
B7-2 are not expressed on rTECs (Waeckerle-Men et al. 2007). On the other
hand rTECs are able to express the coinhibitory molecule PD-L1 and thereby
regulate T cell activity (Starke et al. 2010; Waeckerle-Men et al. 2007). Upon
inflammatory stimulation rTECs themselves secrete cytokines and chemokines.
Amongst these are IL-6, IL-8, RANTES, MCP-1, IL-15 and PAI-1 (Woltman et
al. 2000). These proinflammatory messengers help recruiting immune effector
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cells to the site of injury and enhance their function. This may help to clear
pathogens in the kidney but can cause further tubular injury during allergic in-
terstitial nephritis and accelerate renal allograft rejection (Dugger et al. 2009).
Thus, during renal allograft rejection, not only the interaction between profes-
sional APCs and T or B cells has to be taken into account. Also, the interaction
between effector cells and the major target cells is highly regulated due to the
properties of rTECs.
Objective of this study
Costimulation is an important process during T and B cell activation. It is
known, that blockade of certain costimulatory pathways in combination or alone
is beneficial to prevent allograft rejection (Pilat et al. 2011). This work was
designed to investigate some of the costimulatory processes taking place during
renal allograft rejection.
Blockade of the CD40-CD154 pathway is able to prevent acute allograft rejec-
tion (Quezada et al. 2004), which is mainly mediated by directly alloreactive T
cells (Benichou et al. 1999). We therefore sought to explore the role of CD40
expressed on donor cells in renal allograft rejection. Hereby we not only focused
on CD40 on donor derived APCs, which induce a direct alloresponse. As tubu-
lar epithelial cells are able to express CD40 under certain conditions (Starke et
al. 2007), we also investigated the role of CD40 on them in vitro and in vivo.
The research on CD40-CD154 blockade in murine models so far relies mainly on
a blocking antibody against CD154 (MR1). However, the translation of CD154
blockade into clinics has led to intolerable side effects and is thus not pursued
anymore. It is thus necessary to find tools to block the receptor for CD154
in order to determine, whether CD40 blockade is as efficient as CD154 block-
ade in the well established murine models for tolerance induction and allograft
rejection. As there is so far no anti-CD40 antibody without at least partially ag-
onistic features, we sought to develop a F(ab)-fragment directed against CD40
with exclusively antagonistic properties. We chose to use a monovalent F(ab)-
fragment in order to avoid cross-linkage of the CD40 receptor, which might lead
to activation.
Finally, we investigated the role of the novel costimulatory molecule DNAM-1.
It has been shown, that DNAM-1 ligation is crucial for the cytotoxic activity
of CTLs against non-professional APCs (Gilfillan et al. 2008). As rTECs can
act as non-professional APCs under inflammatory conditions and are the major
targets of CTLs during interstitial rejection, we analyzed, if there is a relevance
of the DNAM-1 pathway in the process of renal allograft rejection.
Introduction 34
35
Chapter 2
Results
Results 36
Section 1
Absence of donor CD40 inhibits allospecific CD8 and
Th17 responses and protects renal allograft epithe-
lium
Anna K. Kraus1,2, Pietro E. Cippa`1,2, Ariana Gaspert3, Jin Chen1,2, Ilka Edenhofer1,4,
Rudolf P. Wu¨thrich1,2, Maja T. Lindenmeyer1,2, Stephan Segerer2,4, Thomas
Fehr1,2
1 Institute of Physiology, University of Zurich, Switzerland
2 Division of Nephrology, University Hospital Zurich, Switzerland
3 Institute of Surgical Pathology, University Hospital Zurich, Switzerland
4 Institute of Anatomy, University of Zurich, Switzerland
Status of this manuscript:
Submitted to Transplantation, 16.02.2012
Contribution to this manuscript:
All experiments, except renal allografts, histology, and immunohistochemistry
were performed by Anna K. Kraus. The manuscript was written and the figures
were made by Anna K. Kraus.
Abstract
Blocking the CD40-CD154 pathway is efficient in various experimental mod-
els to prevent allograft rejection and induce donor-specific tolerance. However,
the translation to clinical studies has been hampered by unexpected throm-
boembolic complications of CD154-blocking antibodies. Thus, blocking CD40
instead is now considered as an alternative strategy. Here we evaluated the role
of donor CD40 in allospecific T cell responses in vitro and in vivo. Absence of
donor CD40 reduced all effector functions of allospecific T cells in vitro. Donor
CD40 expression was essential for the induction of allospecific Th17 cells. In-
terestingly, CD8 T cells required direct CD154 ligation by allogeneic dendritic
cells in order to become fully activated, even in the presence of functional CD4
help. As a result absence of CD40 led to prolonged survival of MHC class I-
mismatched skin grafts. Furthermore, fully MHC mismatched renal allografts
from CD40 knock-out (KO) donors displayed better renal function despite his-
tological findings comparable to wild type allografts. These functional data
correlated with a lower level of apoptosis in renal tubular cells and higher ex-
pression of PD-L1. In conclusion, CD40 blockade not only reduces the allospe-
cific T cell responses, but may also lead to protection of tubular epithelium
from apoptosis and thereby preserve kidney allograft function.
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Introduction
Kidney transplantation is the preferred therapy for end stage renal disease
(Wolfe et al. 1999). Despite improvements in early graft survival, chronic re-
jection and toxicity of classical immunosuppressant drugs remain major reasons
for late allograft loss (Hariharan et al. 2000). Thus, there is a need for more
specific and less toxic immunosuppression regimens. Blockade of the CD40-
CD154-pathway represents a promising target to achieve this goal. It has been
shown that blockade of CD154 together with blockade of B7-molecules (CD80
and CD86) lead to long-term graft survival in murine and non-human primate
models of skin and renal allografts (Kirk et al. 1997; Larsen et al. 1996). Fur-
thermore CD154 blockade was used in several protocols for tolerance induction
using donor specific transfusion (Markees et al. 1997; Rossini et al. 1996) or
bone marrow transplantation (Fehr et al. 2005; Takeuchi et al. 2004; Wekerle
et al. 1999). Many murine protocols for tolerance induction used a mono-
clonal antibody directed against CD154 (MR1). However, translation of the
anti-CD154 reagent into non-human primate and human studies revealed an
unexpected complication of thromboembolic events (Kawai et al. 2000; Knech-
tle et al. 2001), which were due to platelet activation (Koyama et al. 2004).
Thus, CD40 instead of its ligand turned into an attractive target (Badell et al.
2012 ; Page et al. 2012).
Renal tubular epithelial cells (rTECs) are the main target of alloreactive T
cells during tubulointerstitial rejection of renal allografts (Cornell et al. 2008).
RTECs function as non-professional antigen presenting cells (APCs). They ex-
press MHC class I and II molecules under inflammatory conditions (Wuthrich
et al. 1990). The only classical costimulatory molecule expressed on activated
rTECs is CD40 (Waeckerle-Men et al. 2007), whereas CD80 and CD86 are not.
With this surface expression pattern rTECs become targets for both alloreac-
tive CD8 and CD4 T cells.
The T helper cell population mainly involved in acute rejection is of a Th1 type
characterized by IFN -γ production (Benichou et al. 1999). However, a new
subset of pro-inflammatory Th cells, namely Th17 cells, has come into the focus
of transplant research (Heidt et al. 2010). They are characterized by the expres-
sion of the proinflammatory cytokines IL-17A, IL-17F, IL-21 and IL-22 (Ouyang
et al. 2008). This T cell subtype is important for the clearance of pathogens,
which cannot be adequately cleared by Th1 or Th2 cells, and it has been de-
scribed to play a role in various autoimmune diseases (Crome et al. 2009). IL-17
has been detected in early renal allograft rejection in rats and humans (Loong et
al. 2002). Furthermore, human rTECs stimulated with IL-17 become activated
and in turn start to secrete cytokines like IL-8 and IL-6 (Woltman et al. 2000).
Nevertheless, the exact role of Th17 cells in allograft rejection is not clear.
In this study we investigated the role of donor CD40 during direct alloreactivity
in vitro and in vivo. We demonstrate an important role of donor CD40 expres-
sion for the induction of directly alloreactive cytotoxic T lymphocytes and Th17
cells in vitro. Absence of donor CD40 prolonged MHC class I-mismatched skin
grafts, reduced tubular cell apoptosis and improved kidney function in com-
pletely MHC-mismatched renal allografts.
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Material and Methods
Mice
Wild type (WT) C57BL/6 (B6, H-2b), CD40 knock-out (KO) (B6 background,
H-2b), CD154 KO (B6 background, H-2b), CBA (H-2k), Balb/c (H-2d), and
B6.C-H2-Kbm1/By (bm1, H-2bm1) mice were housed in specific pathogen-free
conditions at the University of Zu¨rich. Bm1 mice express the same H-2 hap-
lotype as B6 (H-2b) except for 7 nucleotide differences in the gene for H-2Kb
resulting in amino acid substitutions at codons 152 (glutamate to alanine), 155
(arginine to tyrosine) and 156 (leucine to tyrosine) (Schulze et al. 1983). IL-
17A KO mice (B6 background, H-2b) were kindly provided by Burkhard Becher
with the permission of Yoichiro Iwakura (Nakae et al. 2002). All animal exper-
iments were performed according to protocols approved by the legal authority
(Veterinary Office of the Canton of Zu¨rich).
rTEC culture
Preparation and primary culture of rTECs were performed as described (Wu-
thrich et al. 1990). In all cytotoxicity experiments primary rTEC targets were
stimulated for 48 hours with murine IFN-β and -γ (both Antigenix America,
Huntington Station, NY, USA) at 100 U/ml each prior to use. For FACS analy-
sis of surface marker expression rTECs were stimulated with indicated concen-
trations of IFN-γ, IL-17A (Antigenix America, Huntignton Station, NY USA)
or an agonistic anti-CD40 monoclonal antibody (mAb) (FGK 4.5, BioXCell,
West Lebanon, NH, USA).
T cell proliferation and cell-mediated lympholysis (CML) assay
T cell proliferation and CML assays were performed using isolated CD4 and
CD8 positive T cells as responders. T cells were stimulated with irradiated
(30 Gy) splenocytes, CD11c positive DCs or splenocytes depleted from CD11c
positive cells from allogeneic and syngeneic mice. Splenocytes were sorted
by magnetic cell separation (MACS) according to the protocols of Miltenyi
Biotec (Bergisch Gladbach, Germany). Purity of sorted cells was confirmed
by fluorescence-activated cell sorting (FACS) analysis. Purity for T cells was
usually > 90% and for DCs > 50%.
T cell proliferation was measured by incorporation of tritium-labeled thymidine
(Perkin Elmer, Waltham, USA) on day (d) 4 of culture. Stimulation indices
were calculated as follows:
Stimulation index =
incorporation allogeneic sample
mean incorporation of syngeneic controls
CML assays were performed on d 5 of culture: 51Chromium (Cr)-labelled, IFN-
stimulated allogeneic rTECs were added to the serially diluted culture for 4
hours (killing phase), and allospecific cytotoxicity was assessed by measurement
of 51Cr release in the supernatant. Allospecific lysis was calculated as:
% specific lysis =
(experimental release − spontaneous release)
(total release − spontaneous release) ∗ 100
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FACS analysis
FACS analysis was performed on a BD-FACSCanto II (Becton Dickinson, Allschwil,
Switzerland). Anti-mouse CD3-FITC, CD4-PE, CD8-APC, CD40-APC, PD-
L1 mAb, secondary anti-Rat FITC, and propidium iodide (PI) were purchased
from eBioscience (Frankfurt, Germany).
Cytokines in cell culture supernatants were quantified using a FlowCytomix set
purchased from eBioscience (Frankfurt, Germany) according to the manufac-
turer’s manual.
mRNA isolation and quantitative PCR (qPCR)
mRNA was isolated from either kidney grafts or naive kidneys stored in RNase-
inhibitor or freshly sorted cells using the RNeasy Mini Kit (Qiagen, Hom-
brechtikon, Switzerland). One µg mRNA was transcribed to cDNA using
the Omniscript reverse transcription Kit (Qiagen). Pre-developed TaqMan
reagents were used for qPCR (Applied Biosystems, Carlsbad, CA, USA) de-
tecting murine PD-L1, IFN-γ, IL-17A, and the reference 18s rRNA. The ex-
pression of candidate genes was normalized to the reference, and fold changes
were calculated in relation to the matching controls unsing the 2−ddCT method.
Skin and kidney grafting
At d 0 full thickness tail skin (about 0.5-1.0 cm2) from donor mice was trans-
planted to the dorsal flank area of recipient mice. Graft rejection was defined
as graft necrosis > 90% of the graft.
Kidney grafts were performed in a life-supporting manner as described in de-
tail previously (Tian et al. 2010). In brief, CBA recipients were bilaterally
nephrectomized and only the right kidney was replaced by a B6 WT or CD40
KO allograft. In this strain combination we performed up to today about 20
allografts and no incidence of spontaneous tolerance was observed. Recipients
were sacrificed one week after transplantation. In order to assess graft function,
plasma urea concentration was measured with the urease/glutamate dehydro-
genase method on a Hitachi Modular P autoanalyzer from Roche diagnostics
(Rotkreuz, Switzerland).
Histology and immunohistochemistry
Histologic examination of all kidney grafts was performed by an experienced re-
nal pathologist blinded to the experimental procedures. Tissues were immersion-
fixed in 4% phosphate buffered formalin and embedded in paraffin. The thick-
ness of sections was 4 µm. The slides were routinely stained with hematoxylin
and eosin (H & E), periodic acid-Schiff stain (PAS) and Elastica-van Gieson
(EvG). In selected cases silver methenamine stain and acid fuchsin orange-G
stain were added.
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Immunohistochemistry for CD3 was performed on paraffin embedded mate-
rial as previously described using a monoclonal rat anti-CD3 anitbody (Clone
CD3-12, AbD serotec, Dusseldorf, Germany) (Vielhauer et al. 2009). For de-
tection of apoptotic cells by immunohistochemistry the monoclonal antibody
F7-26 (Chemicon, International, Inc. Temecula, CA) was used as previously
described (Segerer et al. 2002). F7-26 binds to single-stranded DNA after ther-
mal denaturation. A peroxidase-conjugated monoclonal rat anti-mouse IgM
antibody (Zymed, San Francisco, CA) was used as secondary reagent. Dense,
apoptotic nuclei positive for single stranded DNA were quantified in mouse
renal allografts in 15 high power fields (original magnification ×250).
Statistical analysis
All statistical comparisons were performed with GraphPad Prism 4. Normally
distributed groups were compared using Student’s t test. Groups without Gaus-
sian distribution were compared using the Mann-Whitney test. P < 0.05 was
considered as significant.
Results
Effector functions of directly alloreactive T cells and Th17 induction
depend on donor CD40
To assess direct alloresponses in vitro we cocultured isolated T cells from CBA
mice (H-2k) with irradiated splenocytes from WT B6 or CD40 KO (both H-2b)
donors. Proliferation was reduced, when the stimulator cells did not express
CD40 (Fig. 2.1A). To measure allospecific cytotoxicity CBA T cells were stim-
ulated as described above and then used in a Cr-release assay using IFN-treated
rTECs as targets. Allospecific cytotoxicity was reduced, when the T cells did
not receive a CD40 signal during stimulation (Fig. 2.1B). CD40 on target
rTECs, however, did not influence cytotoxicity (data not shown).
In order to characterize the subtype of allospecific T helper cells generated in
the cocultures described above, we measured cytokine production in the su-
pernatant by multiplex bead assay. A strong induction of IFN-γ production
was detected in cocultures of CBA T cells with WT B6 stimulators, which
was markedly reduced in the absence of CD40 (Fig. 2.1C). Furthermore, we
detected production of IL-6 and subsequently IL-17A. The production of IL-
17A was restricted to CD4 T cells as assessed by ELISA and qPCR (data not
shown) and was strongly inhibited in the absence of donor CD40 (Fig. 2.1D).
Th2 cytokines such as IL-4 and IL-10 were not found in any coculture (data
not shown).
To analyze whether there is coherence between Th17 induction and cytotoxic
activity, we stimulated B6 IL-17A KO CD4 and WT CD8 T cells with com-
pletely MHC-mismatched Balb/c splenocytes and measured proliferation and
cytotoxic activity. Neither proliferation nor cytotoxic activity was affected by
the ability of CD4 T cells to secrete IL-17A (Fig. 2.1E, F).
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Figure 2.1: Directly alloreactive T cells depend on donor CD40. CBA CD4 and CD8
T cells were isolated by MACS and cultured in a ratio of 2:1. T cells were stimulated with
irradiated allogeneic B6 WT or CD40 KO splenocytes. (A) Allospecific T cell proliferation
was measured on d 4 of culture. ***P < 0.0001 (B) Allospecific cytotoxicity was measured on
d 5 in a Cr-release assay against IFN-stimulated rTECs from WT B6 mice. (C, D) Cytokine
content of coculture supernatants was measured on d 4 using a FlowCytomix assay: (C)
IFN-γ, (D) IL-6 and IL-17A concentrations. (E, F) B6 WT and IL-17A KO CD4 and CD8
T cells were isolated by MACS and cultured in a ratio of 2:1. T cells were stimulated with
irradiated allogeneic Balb/c splenocytes. (E) Allospecific proliferation of the indicated T cell
combinations was measured on d 4 of culture. (F) Allospecific cytotoxicity was measured on
d 5 in a Cr-release assay against IFN-stimulated rTECs from Balb/c mice. Representative
data of at least 2 independent experiments are shown
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Combined Th17 and Th1 responses induce a costimulatory state of
rTECs in vitro
rTECs respond to the cytokine milieu surrounding them. When stimulated
with IFN-γ they upregulate MHC molecules, CD40 but also the coinhibitory
molecule PD-L1 (Starke et al. 2007). PD-L1 expression can also be induced by
CD40 activation on human primary rTECs (Chen et al. 2006).
As we detected a strong effect on Th1 and Th17 responses, when stimulating
APCs did not express CD40, we assessed the effect of IFN-γ and IL-17A on the
surface expression pattern of rTECs. When rTECs were stimulated with IL-
17A alone, no alteration of surface expression was detected (data not shown).
Treatment of rTECs with IL-17A in combination with IFN-γ, reduced the ex-
pression of PD-L1 on WT and CD40 KO cells compared to the treatment with
IFN-γ alone (Fig. 2.2A). This reduction was not reversed by stimulating the
CD40 pathway with FGK 4.5 on WT rTECs (Fig. 2.2A). Furthermore, the
expression of CD40 on WT rTECs is induced upon IL-17A addition and was
further increased, when the CD40-pathway is activated (Fig. 2.2B). Thus, a
Th17 response with a concomitant Th1 response renders the surface expression
pattern of rTECs to a rather costimulatory than coinhibitory state.
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Figure 2.2: Th1 and Th17 responses together induce a costimulatory state of
rTECs in vitro. WT B6 and CD40 KO rTECs were cultured with the indicated stimuli for
48 hours (IFN-γ at 100 U/ml, IL-17A at 50 ng/ml, anti-CD40 mAb FGK 4.5 at 20 µg/ml).
Surface expression of PD-L1 (A) and CD40 (B) was assessed by FACS. Mean fluorescence
intensities of triplicates are presented. **P < 0.008, ***P < 0.0003 compared to WT cells
stimulated with IFN-γ alone. $ P < 0.001, $$ P < 0.0005 compared to CD40 KO cells
stimulated with IFN-γ alone. Representative results of three independent experiments are
shown.
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CD4 help and donor CD40 are crucial for induction of directly al-
loreactive CD8 T cells
CD4 T cells provide help to CD8 CTLs by producing stimulatory cytokines (e.g.
IL-2, IFN-γ), but also by licensing DCs to provide proper costimulation to CD8
T cells. This process has been shown to be critically dependent on CD40-CD154
interaction (Bennett et al. 1998; Schoenberger et al. 1998). Consistent with
these studies, significantly lower proliferation was observed, when CD8 T cells
were allospecifically stimulated in the absence of CD4 T cells (Fig. 2.3A),
and cytotoxicity against allogeneic rTECs was completely abolished without T
help (Fig. 2.3B). Importantly, also the remaining proliferation of ”helpless”
CD8 T cells was critically dependent on CD40 expressed on donor APCs (Fig.
2.3C). We therefore suspected that CD8 T cells received a CD40 signal directly
from the APC. To address this question more precisely, we used B6 (H-2b)
CD154 KO T cells and stimulated them with completely MHC mismatched
WT Balb/c splenocytes. When cultured alone, both T cell subsets (CD4 and
CD8) showed reduced proliferation in response to alloantigen, if they were not
able to express CD154 (data not shown). When combining WT or CD154
KO CD8 with CD154 KO CD4 T cells, allospecific proliferation was reduced
- most probably due to impaired CD4 help. However, also the abrogation of
CD154 signaling only in CD8 T cells led to reduced overall proliferation. A
direct interaction between CD40 on CD4 and CD154 on CD8 T cells could be
excluded with a control combining WT CD8 and CD40 KO CD4 T cells (Fig.
2.3D). Thus, this experiment revealed a direct role of CD40 on allo-APCs for
CD8 proliferation, even in the presence of a functional CD4 compartment.
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Figure 2.3: CD4 help and CD40 on the APC are crucial for direct allospecific
CD8 T cell activity. (A) MACS-sorted CBA T cells were stimulated with irradiated B6
WT splenocytes in the indicated combinations. Proliferation was measured on d 4. (B) CBA
CD8 T cells were stimulated with irradiated B6 WT splenocytes in the presence or absence
of syngeneic CD4 T cells (ratio of CD4:CD8 being 2:1). On d 5 of culture a Cr-release assay
against IFN-stimulated rTECs from B6 WT mice was performed. Filled symbols: CD8 T
cells in presence of CD4 help; open symbols: CD8 T cells alone. (C) CBA CD8 T cells were
MACS sorted and cocultured with irradiated B6 or CD40 KO splenocytes. Proliferation was
measured on d 4 of culture. (D) B6 WT or CD154 KO CD4 and CD8 T cells were isolated
by MACS and cultured in a ratio of 2:1. T cells were stimulated with irradiated Balb/c
splenocytes. Allospecific T cell proliferation was measured on d 4 of culture. *P < 0.05,
**P < 0.005, ***P < 0.001. Representative data of at least 3 independent experiments are
shown.
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CD40 on donor DCs is critical for cytotoxic T cell responses in vitro
CD40 is expressed on APCs such as DCs and B cells, two of the major APC-
populations. Using isolated DCs from B6 and CD40 KO mice as stimulators,
allospecific proliferation and cytotoxicity of CBA T cells were induced (Fig.
2.4B and C) comparably to whole splenocytes (Fig. 2.1A) and were reduced,
when the allogeneic DCs did not express CD40 (Fig.2.4B and C). In contrast,
the DC-depleted fraction, which consists mainly of B cells, did not induce pro-
liferation or cytotoxicity independent of CD40 expression (Fig. 2.4B and C).
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Figure 2.4: CD40 on allogeneic DCs is critical for cytotoxic T cell responses in
vitro. CBA CD4 and CD8 T cells were cultured in a ratio of 2:1. Splenic DCs from B6 WT
or CD40 KO animals were isolated using MACS specific for CD11c. The positive and negative
fraction were irradiated and used as stimulators. (A) Proliferation was measured on d 4 of
culture. *P < 0.05 (B) Allospecific cytotoxicity was measured on d 5 in a Cr-release assay
against IFN-stimulated rTECs from B6 WT mice.
The direct CD8 alloresponse depends on donor CD40 in vivo
To evaluate the role of donor CD40 on direct alloreactive CD8 T cells in vivo,
we performed skin grafts from WT B6 or CD40 KO mice to bm1 mice. In this
strain combination Kb is the only mismatched MHC molecule recognized by
directly alloreactive CD8 T cells. A prolongation of graft survival by 6 days
for CD40 KO grafts compared to WT grafts was observed in this model (Fig.
2.5A). This result suggests that donor CD40 is required for full activation of
direct alloreactive CD8 T cells.
To test this experiment in a complete MHC-mismatched situation, we used
CBA mice as recipients for WT B6 or CD40 KO skin grafts (Fig. 2.5B). In this
case, no difference in allograft survival could be detected. Thus, blocking only
donor CD40 is not sufficient to prevent allograft rejection by a graft with MHC
class I and II disparity.
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Figure 2.5: MHC class I-mismatched skin graft survival is prolonged in the ab-
sence of donor CD40. (A) Skin from B6 WT or CD40 KO donors was transplanted on
MHC class I-mismatched bm1 recipients (n = 5 for WT grafts, n = 7 for CD40 KO grafts).
Median survival: 15 vs. 21 days, P = 0.0005. (B) Skin from B6 WT or CD40 KO donors
was transplanted on fully MHC-mismatched CBA recipients (n = 7 for WT grafts, n = 8 for
CD40 KO grafts). Median survival times: WT and CD40 KO: 11 days.
Absence of CD40 on renal grafts leads to improved allograft function
To analyze the effect of donor CD40 on renal allograft rejection in vivo, we
performed life-supporting kidney grafts from WT B6 and CD40 KO donors to
completely MHC-mismatched CBA recipients. Syngeneic transplants were used
as controls. One week post transplantation allogeneic grafts demonstrated se-
vere interstitial infiltrates (Fig. 2.6B and C) and at times prominent tubulitis
(Fig. 2.6H). The infiltrates showed a perivenular accentuation (Fig. 2.6G).
Infiltrates around arteries were common, but signs of acute vascular rejection
(subendothelial infiltrates) were only seen occasionally. CD3 positive T cells as
well as B cells were present in the interstitial infiltrates (CD3 staining shown
in Fig. 2.6D-E, B220 staining not shown). The severity of these findings was
comparable between WT and CD40 KO allografts, whereas syngeneic grafts
did not show any infiltrates (Fig. 2.6A and D). Interestingly, despite any obvi-
ous morphological difference in the conventional histology, recipients of a CD40
KO kidney showed lower blood urea levels compared to those with a WT graft
indicating a better graft function (Fig. 2.6I). Furthermore, these animals dis-
played a better general condition, represented by less body weight loss (data
not shown).
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Figure 2.6: Lack of CD40 on renal allografts leads to improved allograft func-
tion. B6 WT or CD40 KO mice were used as donors for life-supporting kidney grafts to
CBA recipients. Syngeneic controls were performed using B6 WT mice as donor and recipi-
ent. Organs were harvested after 1 week (n = 5 per group). (A) Representative hematoxylin
and eosin stain showing normal renal tissue from a syngeneic graft. (B, C) Representative
pictures of hematoxylin and eosin stainings showing interstitial infiltrates in allogeneic grafts.
(D-F) Representative pictures of immunohistochemistry for murine CD3. (G-H) Representa-
tive pictures of venulitis (G) and tubulitis (H) in allografts. Arrows indicate intraepithelial
lymphocytes (H). Magnifications are indicated. (I) Urea concentration in serum of recipients
was determined on harvest day.
To further determine the reason for this functional difference, we first examined
the intragraft expression levels of inflammatory cytokines such as IFN-γ and IL-
17A by qPCR. IFN-γ expression was highly induced in allografts independently
of their CD40 expression (Fig. 2.7A). IL-17A was only detectable at very low
levels (Fig. 2.7B), and also no difference between WT and CD40 KO grafts was
found.
We have previously shown that rTECs, dependent on the surrounding cytokine
milieu, do express the costimulatory CD40, but also the coinhibitory PD-L1
(Fig. 2.2) (Starke et al. 2007). We therefore tested for PD-L1 expression in
the kidney grafts by qPCR. PD-L1 expression was increased in the CD40 KO
allografts compared to the WT group (Fig. 2.7C). Furthermore, we detected a
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lower amount of apoptotic epithelial cells in this group (Fig. 2.7D and E). Thus,
rTECs in a CD40 KO allograft seem to be partially protected from the attack
of alloreactive T cells, and this might be mediated by PD-L1, as previously
shown in humans (Starke et al. 2010).
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Figure 2.7: Higher expression of PD-L1 and less apoptosis in CD40 KO renal
allografts. B6 WT or CD40 KO mice were used as donors for life supporting kidney grafts to
CBA recipients. Syngeneic controls were performed using B6 WT mice as donor and recipient.
Organs were harvested at 1 week (n = 5 per group). (A-C) Intragraft mRNA expression levels
of IFN-γ (A), IL-17A (B), and PD-L1 (C) were detected by qPCR. All results are shown as
fold change to naive control kidney samples. (D, E) Immunohistochemistry for ssDNA was
performed on all grafts. Quantitative analysis (D) and representative pictures (magnification:
×400) (E) are displayed. Arrows indicate apoptotic cells. In all experiments groups were
compared using a Man-Whitney test. No significant differences between WT and CD40 KO
groups could be detected.
Discussion
Directly alloreactive T cells are important effector cells causing acute rejection
of solid organ allografts (Benichou et al. 1999). In this study we demonstrate
a dependence of directly alloreactive T cells on CD40 expressed on donor cells.
All effector functions including proliferation, cytokine production, and cytotox-
icity were reduced in the absence of CD40 on donor APCs. This was also true
for alloreactive CD8 T cells. A connection was found between CD40 signaling
and the induction of Th17 cells in vitro. In vivo, absence of donor CD40 led
to prolonged survival of MHC class I-mismatched skin allografts and improved
function of fully mismatched renal allografts, potentially mediated by PD-L1-
dependent protection of rTECs from apoptosis.
An important role of Th17 cells in response to bacterial pathogens and au-
toimmune diseases is nowadays widely accepted (reviewed in (Hu et al. 2010)).
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However, their role in allograft rejection is not completely established yet. The
most convincing studies showing, that IL-17 producing T cells can cause allo-
graft rejection, were performed in mice lacking the Th1 specific transcription
factor T-bet (Burrell et al. 2008; Yuan et al. 2008). However, it remains
unclear, whether the processes observed in these studies are also taking place
in animals sufficient in Th1 responses. Moreover, the impact of IL-17 on the
intragraft modulation of the immune response in renal allografts remains to be
further investigated.
It has been shown that the induction of virus-specific Th17 cells is dependent
on antigen dose and TLR triggering in the APCs, and this process is boosted
by triggering CD40 and completely abolished, when CD40 signaling is blocked
(Iezzi et al. 2009). In our study, we show for the first time that the same is also
true for alloreactive T cells. However, we found that the ability of CD4 cells to
produce IL-17A is not required to induce full cytotoxic activity in CD8 T cells.
This finding is supported by a recent publication of a tumor model, in which
Th17 cells help to activate CD8 T cells, but this process was independent of IL-
17A and rather mediated by IL-2 and indirect presentation of antigen on MHC
class I molecules of the CD4 helpers (Ankathatti Munegowda et al. 2010).
When searching for IL-17A expression in acutely rejecting renal allografts, we
detected only very low amounts, with no difference between WT and CD40 KO
allografts. This might be due to the time point of measurement. Loong et al.
detected IL-17 producing mononuclear cells in renal allografts as early as day
2 after transplantation (Loong et al. 2002). We harvested the renal allografts
only at day 7, and this time point might be too late to detect the described
effects.
The role of CD40 signaling for T cell activation has been widely studied and
in the case of CD4 T cells its role for their activation and cross-talk with B
cells is firmly established. However, the role of CD40 signaling to CD8 T cells
is less clear. In our model we found that directly alloreactive CD8 T cells not
only depended on CD4 help, but also needed a CD40 signal from the donor
APCs for complete activation. This result is consistent with an earlier study
performed in CD154 KO animals (Zhai et al. 2002). However, these animals
also lack CD154 on CD4 T cells leading to impaired CD4 help. Here we show
for the first time dependency of alloreactive CD8 T cell activity on CD40 sig-
naling in vitro, even when CD4 help is intact. Similarly Hernandez et al. found
a reduced activation of virus-specific CD8 T cells in vivo, when CD40-CD154
interaction was disabled specifically between CD8 T cells and DCs (Hernandez
et al. 2007).
We showed that CD40 expression on donor cells is necessary for cytotoxic CD8
activity during the induction phase. The cells mediating this effect were donor
DCs. Tissue residing DCs are the most prominent population of passenger
leukocytes. Thus, CD40 blockade early after transplantation might reduce in-
duction of directly alloreactive CD8 T cells by this stimulator population. This
is supported by the results obtained in a skin graft model, which is mainly
restricted to directly alloreactive CD8 activity. A significant, although rather
mild effect on graft survival was observed, which correlated with the in vitro
results, where cytotoxicity was also significantly reduced, but not abolished,
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when the stimulator cells did not express CD40.
Despite reduction of alloreactive T cell responses in vitro, severity of kidney
allograft rejection assessed by conventional histology was not altered, when the
allograft did not express CD40. Also intragraft levels of proinflammatory cy-
tokines (IFN-γ and IL-17A) were identical. Limiting to the model used here is
the fact, that one cannot exclude indirect or semi-direct alloantigen presenta-
tion on syngeneic APCs with normal CD40 expression. However, we detected
improved function of CD40 KO kidney allografts 7 days post-transplantation.
rTECs express CD40 under inflammatory conditions. When CD40 is triggered,
this leads to activation and subsequent production of inflammatory molecules,
such as IL-6, IL-8, RANTES, MCP-1, IL-15 and PAI-1 (Woltman et al. 2000).
These chemokines and cytokines in turn can cause tubular injury and acceler-
ate renal allograft rejection (Dugger et al. 2009). The fact that we found less
apoptotic rTECs in CD40 KO grafts, suggests that these cells were partially
protected from this process. Similar results were described in a study of chronic
proteinuric renal disease, where blockade of CD154 with MR1 led to ameliora-
tion of disease (Kairaitis et al. 2003). Another reason for less apoptosis found
in CD40 KO grafts could be the higher expression of the inhibitory ligand PD-
L1. The expression of PD-L1 has been shown to protect human rTECs from
allospecific CD8 cytotoxic activity (Starke et al. 2010). In vitro we showed
that IL-17A stimulation in the presence of IFN-γ induces a reduction in PD-L1
expression on rTECs, which is accompanied by an upregulation of CD40 on
WT cells. If our in vitro results concerning the reduced Th17 induction by
CD40 KO donor cells are true also for this in vivo model, one would expect
a reduced Th17 response in recipients of CD40 KO allografts. The reduced
PD-L1 expression in WT allografts might consequently be due to a higher IL-
17A concentration early after engraftment concomitant with the high IFN-γ
concentration that we found. Thus, the rTECs in WT B6 allografts adopted a
more costimulatory then inhibitory state and were more susceptible to T cell
mediated cytotoxicity.
We postulate that these two mechanisms - less activation and better protection
from CTLs - lead to a better preserved renal function in CD40 KO renal allo-
grafts. Whether the surface expression pattern of PD-L1 and CD40 and lower
apoptosis level are directly linked in this model needs to be further investigated.
Taken together, our results indicate that blocking donor CD40 not only reduced
directly alloreactive CD8 T cell responses and Th17 induction, but might addi-
tionally prevent rTEC activation and killing resulting in preservation of allograft
function. Considering the complications, which blockade of CD154 caused in
non-human primates and in humans (Kawai et al. 2000), the blockade of CD40
itself may be a more promising strategy to prevent renal allograft rejection.
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Abstract
Blocking the CD40-CD154 costimulation pathway is a promising tool for in-
duction of immunologic tolerance - either to auto- or allo-antigens - or as an
alternative to current immunosuppressive treatments. So far most strategies
relied on blocking CD154. This, however, has become impossible to use in
humans because of thromboembolic events obsereved in the first trials. Thus,
CD40 blockade is now in focus of research. Some human or chimeric antibodies
against CD40 have already been tested in transplantation models in non-human
primates. For mouse, the most used model organism, there are no antibodies
against CD40 without activating properties. We therefore developed a F(ab)-
fragment binding firmly to murine CD40 without activating CD40 signaling and
thereby the cell expressing it. F(ab)86 is able to block CD40 induced signal-
ing, proliferation, and activation in murine B cells. Furthermore, it is a potent
inhibitor of allospecific T cell proliferation and Th17 induction in vitro.
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Introduction
Costimulation blockade is a promising strategy to induce tolerance to various
antigens. Especially the blockade of the CD40-CD154 pathway showed good
results in several preclinical models for autoimmune diseases and transplanta-
tion.
Several autoimmune diseases have been shown to at least partially depend on
the CD40-CD154 costimulatory pathway. CD40 and CD154 positive cells have
been shown to be present in white matter lesions in multiple sclerosis (MS), and
blockade of CD154 was able to ameliorate EAE, a model for MS (Gerritse et al.
1996). Also, in models for SLE blockade of CD154 postpones onset of disease
in susceptible mice (Mohan et al. 1995), and CD28 pathway blockade further
enhances this effect (Daikh et al. 1997). Finally, in a model for autoimmune
arthritis, RNAi-mediated CD40-CD154 interruption led to antigen specific tol-
erance and prevented disease onset (Zheng et al. 2010).
Induction of antigen-specific tolerance is a major goal in transplantation im-
munology. Despite the improvements of immunosuppressive treatment and re-
duction of acute rejection episodes during the first year of transplantation in
renal transplantation, many grafts are lost in the long term due to rejection
or the toxic effects of immunosuppressive drugs (Hariharan et al. 2000). The
induction of donor-specific tolerance would solve both problems. Several exper-
imental protocols are used in murine and non-human primate models for solid
organ transplantation. Most of them contain blockade of the CD40-CD154
pathway. These include simultaneous blockade of the CD40 and CD28 path-
ways at the time of transplantation (Kirk et al. 1997; Larsen et al. 1996).
Others use DST under CD154 blockade (Markees et al. 1997; Phillips et al.
2003). A protocol combining anti-CD154, DST and an mTOR-inhibitor has
been successfully translated into a non-human primate model for renal trans-
plantation (Preston et al. 2005). Finally, the induction of mixed chimerism
to achieve stable donor specific tolerance is pursued. For this approach the
actual minimal treatment protocols in mice is using CD154 blockade combined
with non-myeloablative irradiation and bone marrow transplantation (Fehr et
al. 2005; Takeuchi et al. 2004; Wekerle et al. 1999).
Almost all mentioned applications for CD40-CD154 blockade are dependent on
antibodies against CD154. However, the use of a blocking CD154 antibody has
led to unexpected thromboembolic events in clinical trials (Kawai et al. 2000;
Knechtle et al. 2001), which were due to platelet activation by the administered
antibody (Koyama et al. 2004). Therefore, efforts were made to find antibodies
blocking CD40 and these were successful in non-human primates (Badell et al.
2012; t Hart et al. 2005). Up to today only antibodies with agonistic activities
are available against murine CD40 (e.g. FGK4.5, 3/23, or HM40-3). These mul-
tivalent antibodies have the ability to crosslink CD40 and thereby activate it.
Furthermore, the administration of antibodies in patients is not problem-free:
immunogenicity of not completely humanized antibodies and infusion reactions
have been observed with translation to the clinics (Ferran et al. 1991; Helliwell
and Coles 2009).
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In this study we therefore searched to identify a monovalent F(ab)-fragment spe-
cific for murine CD40 with antagonisitic properties. In cooperation with AbD
Serotec, we found four candidate molecules by phage display library screening.
From these four candidates, one molecule was chosen according to its binding
properties and activity. This fragment showed a potent ability to block CD40
signaling in B cells and allospecific T cell activation.
Material and Methods
Mice
C57BL/6 (B6, H-2b), CD40 knock out (CD40 KO, B6 background, H-2b), and
CBA (H-2k), mice were housed in specific pathogen-free conditions at the Uni-
versity of Zu¨rich. All animal experiments were performed according to protocols
approved by the legal authority (Veterinary Office of the Canton of Zu¨rich).
Proliferation assays
T cell proliferation assays were performed using isolated CD4 and CD8 posi-
tive T cells as responders. T cells were sorted from whole spleen by magnetic
cell separation (MACS) according to the protocols of Miltenyi Biotec (Bergisch
Gladbach, Germany). Purity of sorted cells was confirmed by FACS analysis. T
cells were then stimulated with irradiated (30 Gy) splenocytes from allogeneic
and syngeneic mice.
Proliferation was measured by incorporation of tritium-labeled thymidine (Perkin
Elmer, Waltham, USA) on day 4 of culture. Stimulation indices were calculated
as follows:
Stimulation index =
incorporation allogeneic sample
mean incorporation of syngeneic controls
B cell proliferation assays were performed using MACS-isolated B cells. B
cells were stimulated with a monoclonal anti-IgM antibody (II/41, eBioscience,
Frankfurt, Germany) or an anti IgM-F(ab)2-Fragment (polyclonal, Jackson Im-
munoresearch Europe, Suffolk, UK) coated on the plate at 1 µg/ml in phosphate
buffered saline (PBS) over night and a soluble monoclonal anti-CD40 antibody
(FGK4.5, Bioxcell, West Lebanon, NH, USA) at 5 µg/ml.
FACS and cytokine quantification
FACS was performed with a BD-FACSCanto II (Becton Dickinson, Allschwil,
Switzerland). Anti-mouse CD3-FITC, CD4-PE, CD8-APC, CD45R/B220-PE,
CD45/B220-PE-Cy7, CD86-PE, and propidium iodide (PI) were purchased
from eBioscience (Frankfurt, Germany), carboxyfluorescein succinimidyl es-
ter (CFSE) from Promega (Du¨bendorf, Switzerland). A PE-labeled antibody
against a 6×His-Tag was purchased from Abcam (Cambridge, UK). Analysis of
raw data was performed using FlowJo 7.6.1 software (Tree star Inc., Ashland,
OR, USA).
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Cytokines from cell culture supernatants were quantified using a FlowCytomix
set purchased from eBioscience (Frankfurt, Germany) according to the manu-
facturer’s manual.
Antigen production and phage display library screen
The murine plastocytoma cell line expressing mCD40-huγ1, a fusion protein
consisting of murine CD40 linked to a human IgG heavy chain, was kindly
provided by David Gray (Gray et al. 1994). The fusion protein was purified
from cell culture supernatants using a gravity flow protein A column accord-
ing to manufacturer’s instructions (Thermo Fisher Scientific Inc., Rockford, IL,
USA). The resulting protein solution was rebuffered to PBS. Protein concentra-
tion was measured using a BCA assay (Thermo Fisher Scientific Inc., Rockford,
IL, USA). Purity of the fusion protein was detected by SDS polyacrylamide gel
electrophoresis.
The mCD40-huγ1 protein together with the negative control (human IgG heavy
chain) served as target for a screen of the HuCAL r PLATINUM phage display
library (Knappik et al. 2000, Prassler et al. 2011) performed by AbD Serotec
(Puchheim, Germany). Binding of the resulting F(ab)-fragments to the target
was proven by ELISA performed by AbD Serotec (Puchheim, Germany).
Chemicals
Phorbol12-myristate13-acetate (PMA) and ionomycin were purchased from Sigma
Aldrich (Buchs, Switzerland) and used at 50 ng/ml and 500 ng/ml, respectively.
Western blotting
Western blot analysis was performed using mouse anti IκB alpha antibody
(Abcam, Cambridge, UK) and a mouse anti β-tubulin antibody (Sigma Aldrich,
Buchs, Switzerland). A peroxidase-conjugated goat anti-mouse IgG was used as
secondary reagent. Determination of band density was performed using ImageJ
software (Wayne Rasband, National Institute of Health, USA).
Statistical analysis
All statistical comparisons were performed with GraphPad Prism 4. Normally
distributed groups were compared using Student’s t test. Groups without Gaus-
sian distribution were compared using the Mann-Whitney test. P < 0.05 was
considered significant.
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Results
Generation of blocking F(ab)-fragments against murine CD40
As target protein for a phage display library screen of the HuCAL r PLAT-
INUM library performed by AbD Serotec we used a fusion protein consisting
of murine CD40 and a human IgG heavy chain (mCD40-huγ1). MCD40-huγ1
was purified from cell culture supernatant of the stably transfected plastocy-
toma cell line using a protein A column, which binds specifically the human IgG
heavy chain in the fusion protein. After rebuffering to PBS, purity of the gained
protein was analyzed by SDS polyacrylamide gel electrophoresis (Fig. 2.8A).
This protein together with a negative control (human IgG heavy chain) was
sent to AbD Serotec as target for the phage display library screen. Four candi-
date F(ab)-fragments were obtained from this. Their binding to mCD40-huγ1
was proved by ELISA performed by AbD Serotec (Fig. 2.8B). F(ab)-fragment
AbD0866786.1 (F(ab)86) bount the target with the highest affinity.
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Figure 2.8: Screening for a blocking anti-CD40 F(ab)-fragment. (A) mCD40-huγ1
was purified over a protein A column and rebuffered to PBS. Purity was analyzed by SDS
polyacrylamide gel electrophoresis. (B) Binding of the four F(ab)-fragment candidates to
mCD40-huγ was assessed by ELISA performed by AbD Serotec. Human IgG heavy chain
alone, BSA and GST were used as negative controls.
Screening for the best candidate F(ab)
B cells express CD40. To identify the best of these four candidate fragments,
we used murine B cells and analyzed binding and proliferation inhibition as
readouts. All fragments were incubated with B6 splenocytes and detected with
an antibody against the 6×His-Tag, which all fragments contained. All four
fragments bound to B cells (Fig. 2.9A). The strongest binder was F(ab)86
(Fig. 2.9A). This correlated with the results for solid phase binding obtained
by ELISA performed by AbD Serotec.
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We then performed a functional screen using a B cell proliferation assay based on
CFSE dilution. MACS-isolated B cells were labeled with CFSE and stimulated
with a plate bound anti-IgM and a soluble anti-CD40 antibody (FGK4.5). After
four days the cells were harvested and CFSE dilution was detected by FACS.
Combined stimulation of IgM and CD40 induced B cell proliferation. This
could be blocked most efficiently by F(ab)86 (Fig. 2.9B), but not with the
other candidate fragments. Thus, we chose F(ab)86 to proceed with further
experiments.
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Figure 2.9: Screening for a blocking anti-CD40 F(ab)-fragment. (A) Splenocytes
from B6 mice were incubated with equal amounts of all four candidate F(ab) fragments.
Binding of F(ab)-fragments to B220 prositive B cells was detected with a secondary antibody
directed against the 6×His-Tag and analyzed by FACS. Mean fluorescence intensities (MFIs)
are indicated. (B) Isolated splenic B cells from B6 mice were labeled with CFSE and stimulated
with plate bound anti-IgM antibody (1 µg/ml) and soluble FGK4.5 (5 µg/ml) or left untreated
for 4 days. F(ab)-fragment candidates were added from the beginning of culture at 5 µg/ml.
Proliferation was assessed by CFSE dilution in FACS.
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F(ab)86 reduces CD40 driven B cell activation and proliferation
We used the more sensitive method of 3H-thymidine-incorporation to measure
B cell proliferation. Isolated B cells were stimulated with plate-bound anti-IgM
and soluble FGK4.5. Proliferation was measured on day 4. Titrated amounts
of Fab(86) were added to the culture in order to block B cell activation and
proliferation. At a concentration of 5 µg/ml F(ab)86 reduced B cell prolifera-
tion to negative control level (Fig. 2.10A).
To assess B cell activation we assessed the expression of the activation marker
CD86 on day 4 of stimulating culture. F(ab)86 strongly reduced upregulation
of CD86 induced by CD40 stimulation from a concentration of 5 µg/ml (Fig.
2.10B). The median fluorescence intensity was reduced from 101 for the stimu-
lated control to 18 at 5 µg/ml or 16.3 at 10 µg/ml (median fluorescence intensity
untreated control: 9.46).Figure 2
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Figure 2.10: F(ab)86 reduces CD40 driven activation and proliferation. Isolated
splenic B cells from B6 mice were stimulated with plate bound anti-IgM F(ab)2-fragment
(1 µg/ml) and soluble FGK4.5 (5 µg/ml) or left untreated for 4 days. Titrated amounts of
F(ab)86 was added to stimulating cultures at indicated concentrations. (A) Proliferation was
measured by 3H-Thymidine incorporation. * P < 0.015. (B) Expression of the activation
marker CD86 was assessed by FACS.
F(ab)86 blocks CD40-induced NFκB signaling
Trimerization-induced recruitment of tumor necrosis factor receptor associated
factors (TRAFs) 2, 3, 5, and/or 6 to the cytoplasmic domain of CD40 triggers
the canonical NFκB pathway, which induces the ubiquitin- and proteasome-
dependent degradation of IκB and the subsequent release of NFκB, which then
translocates to the nucleus (Elgueta et al. 2009). We therefore tested, if F(ab)86
is able to block the degradation of IκB. Isolated splenic B cells were incubated
on plate-bound FGK4.5 for 2 hours. F(ab)86 was added at indicated concentra-
tions from the beginning. Protein lysates were prepared and used for a western
blot specific for IκB. As positive control we used B cells stimulated with PMA
and ionomycin. IκB degradation in B cells was induced after 2 hours of incuba-
tion with FGK4.5 (Fig. 2.11A and B). This was reversed and IκB content was
restored already at a concentration of 5 µg/ml F(ab)86 (Fig. 2.11A and B).
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Figure 2.11: F(ab)86 blocks NFκB signaling. Isolated splenic B cells from B6 mice
were incubated on plate bound FGK4.5 (5 µg/ml) for 2 hours and F(ab)86 was added at
indicated concentrations. IκB content of the cytoplasm was detected by western blot. As
loading control staining for β-tubulin was used. (A) Representative western blot for IκB. (B)
Density measurement was performed using the ImageJ software. Density of IκB bands was
normalized to that of β-tubulin bands, and IκB content of untreated B cells was set as 100%.
Relative content of IκB in treated B cells is shown.
F(ab)86 blocks allospecific T cell activation and Th17 induction
The CD40-CD154 pathway is also important for the priming of T cells. Not
only does CD154 expressed on the T cell give an activation signal to the T cell
(van Essen et al. 1995), but also the engagement of CD40 leads to activation
and further upregulation of costimulatory molecules on the APC (Quezada et
al. 2004). We therefore tested, if blocking CD40 with F(ab)86 can reduce
allospecific T cell proliferation in vitro. CBA T cells (H-2k) were isolated and
stimulated with completely MHC-mismatched splenocytes from B6 mice (H-
2b). As controls we used stimulators deficient in CD40 (H-2b) and syngeneic
splenocytes. The addition of F(ab)86 reduced allospecific T cell proliferation
in a dose-dependent manner. At 10 µg/ml T cell proliferation was similar as
when using CD40 KO stimulators. We have previously shown that in a similar
in vitro assay the induction of Th1 cells is partially and the one of Th17 cells
critically dependent on CD40 expression on the stimulator cells (see section 2).
We thus measured cytokine content in the supernatants of these cocultures. For
IFN-γ a reduction to the level achieved with CD40 KO stimulators was reached
already at 1 µg/ml F(ab)86 (Fig. 2.12B). Addition of the higher concentration
further reduced IFN-γ to a non detectable amount (Fig. 2.12B). The induction
of Th17 cells was monitored by the production of IL-6 and IL-17A. Complete
blockade of Th17 development needed a higher concentration of F(ab)86 and
was achieved at 10 µg/ml (Fig. 2.12B).
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Figure 2.12: F(ab)86 reduces allospecific T cell proliferation. Isolated splenic CD4
and CD8 T cells from CBA mice (H-2k) (ratio 2:1) were stimulated with irradiated (30 Gy)
splenocytes from B6 mice (H-2b). F(ab) 86 was added at indicated concentrations from the
beginning of culture. As controls stimulators from allogeneic CD40 KO (H-2b) and syngeneic
cells were used. (A) Proliferation was measured by 3H-thymidine incorporation on day 4.
Stimulation indices relative to syngeneic control are shown. *P < 0.04, **P < 0.004. (B)
Supernatants of cocultures were analyzed for cytokine content on day 4 using a multiplex bead
assay. Concentrations for IFN-γ (left axis), IL-17A, and IL-6 (right axis) are shown. ND=not
detectable
Discussion
In this study we identified an F(ab) fragment directed against murine CD40
with blocking properties. F(ab)86 was able to block B cell activation and pro-
liferation. We showed that this is due to blockade of CD40 downstream signal-
ing. Furthermore, F(ab)86 blocked directly allospecific T cell proliferation and
cytokine production in the same way as the use of CD40 KO stimulators does.
The blockade of CD154 appeared as a very promising tool to induce allospecific
tolerance or to ameliorate several autoimmune diseases (Fehr et al. 2005; Ger-
ritse et al. 1996; Kirk et al. 1997; Larsen et al. 1996; Markees et al. 1997; Mo-
han et al. 1995; Phillips et al. 2003; Preston et al. 2005; Takeuchi et al. 2004;
Wekerle et al. 1999). Unfortunately, the translation of CD154 blockade into
clinics in studies with renal transplant recipients led to severe thromboembolic
events (Knechtle et al. 2001), which was concomitantly observed in non-human
primates (Kawai et al. 2000), and was eventually stopped. These events have
been found to be due to the activation of CD154 on platelets (Koyama et al.
2004).
As all previous attempts to block the CD40-CD154 pathway relied on antibod-
ies binding to CD154, it was questionable if blocking CD40 is just as effective as
blocking CD154. Various antibodies directed against CD40 have already been
tested in nonhuman primates. Chi220, a chimeric antibody directed against
human CD40 allowed extended islet allograft survival in synergy with CTLA4-
Ig (Adams et al. 2005). However, this antibody is B cell-depleting (Adams et
al. 2005). Recently, another anti-CD40 antibody 3A8 was successfully tested
in islet transplantation and induction of mixed chimerism in rhesus macaques
(Badell et al. 2012; Page et al. 2012). 3A8 is a mouse antibody directed against
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human CD40, which is not B cell-depleting. 3A8 was able to suppress allospe-
cific T cell proliferation. However, it was not able to block binding of soluble
CD154 to CD40, and it induced upregulation of B7 molecules on B cells in
vitro (Badell et al. 2011). Still, the results from studies using these antibodies
indicate that blockade of the CD40/CD154 pathway on the receptor side is as
beneficial as blocking the ligand CD154.
In fact, we showed that F(ab)86 is a potent inhibitor of B and T cell activation
in vitro due to its ability to bind CD40 without activating it. Th17 cells have
been shown to play a role in the pathogenesis of several autoimmune diseases.
Furthermore, Iezzi et al. showed that the CD40-CD154 pathway is crucial for
the induction of Th17 cells in a murine EAE model (Iezzi et al. 2009). F(ab)86
is not only capable of inhibiting T cell proliferation. We also detected a strong
inhibition of Th17 induction. Blocking induction of this T cell subset might
therefore be another promising application of F(ab)86.
Monoclonal antibodies found their way into clinics for many different diseases
(Getts et al. 2010). However, even if these antibodies are humanized, some of
them are still immunogenic and induce anti-drug antibodies. These can reduce
treatment efficacy or lead to acute infusion reactions (anaphylaxis due to anti-
drug antibodies) (Maggi et al. 2011). Some therapeutic antibodies also result
in a strong cytokine release upon infusion (Maggi et al. 2011). Finally, partially
agonistic polyvalent antibodies against costimulatory molecules bear the risk of
inflammatory reactions, as shown for an anti-CD28 antibody (Suntharalingm et
al. 2006). We therefore chose to use an F(ab)-fragment, which avoids receptor
mutlimerization and is less immunogenic. However, one significant limitation
of F(ab)-fragments is their short half-life in vivo. This can be prolonged by
modification of the compound. One option for this is pegylation. In this case
the polyethylene glycol chains of variable size and grade of branching are bound
covalently to the F(ab)-fragment. Thereby size and hydrophily are increased
and immunogenicity decreased (Veronese 2002). Similary modified cytokines,
for example IFN-α for the treatment of hepatitis B and C, are already in clinics
for several years (Papatheodoridis and Cholongitas 2004). However, pegylation
has also been successfully used to increase the half life of an F(ab)2-fragment
directed against IL-8 (Koumenis et al. 2000) and various F(ab)-fragments in
rodent studies (Baer et al. 2009; Chapman et al. 1999). Finally, a pegylated
F(ab)-fragment directed against human TNF-α made its way to the clinics for
treatment of rheumatoid arthritis and Crohn’s disease (Choy et al. 2002; Sand-
born et al. 2007). Another option for an increase in half life would be the
generation of a fusion protein containing F(ab)86 and a bigger but rather inert
fusion partner like albumin (Smith et al. 2001) or α1-antitrypsin (Vanhove et
al. 2003). The latter has been pursued for an Fv-single chain directed against
human CD28. Functionality of the Fv-fragment was given and half life could
be extended to a useful amount of time (Vanhove et al. 2003).
Taken together, F(ab)86 is a potent tool to study CD40 blockade in murine
models for tolerance induction and autoimmune diseases. Because the screen-
ing and selection are quickly to do using the phage display library we used,
translation of this approach into larger animals and humans seems feasible.
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Abstract
A new costimulatory pathway is emerging in the field of transplantation re-
search. DNAM-1 and its two ligands have been shown to mediate NK and T
cell killing of tumor cells and non professional antigen presenting cells. Blockade
of DNAM-1 was beneficial in a model for graft-versus-host disease. Therefore,
we tested the importance of DNAM-1 and its two ligands (CD155 and CD112)
in renal allograft rejection. We show that both ligands for DNAM-1 are ex-
pressed on renal tubular epithelial cells and upregulated in acutely rejected
renal allografts and under inflammatory conditions in vitro. In vitro we de-
tected a role for DNAM-1 in allospecific T cell priming, which however was
independent from the ligation of CD155 or CD112. Furthermore, allospecific
cytotoxicity against rTECs was independent of DNAM-1 ligation by the tar-
gets. In in vivo models for solid organ rejection, there was also no effect on
severity of allograft rejection, when DNAM-1 ligands were missing. However, in
renal allografts deficient in CD155 or CD112, we detected a higher incidence of
infarcts indicating endothelial damage. Thus, the blockade of DNAM-1 itself,
but not of its ligands might be beneficial in solid organ transplantation.
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Introduction
Kidney transplantation is the best therapy option for end stage renal disease
(ESRD) (Wolfe et al. 1999). Despite improvement of first year graft survival,
a lot of grafts are lost in the long term due to rejection and the toxicity of
classical immunosuppressant drugs (Hariharan et al. 2000). Therefore there is
a need for better understanding of the processes that lead to rejection and for
new strategies to achieve more specific and less toxic immunosuppression.
For complete activation T cells do not only need the signal via the T cell re-
ceptor but also costimulatory signals which can be delivered through several
receptors. Costimulation blockade has therefore become a promising tool for
immunosuppression and/or tolerance induction in solid organ transplantation.
Latest developments focussed mainly on the classical costimulatory molecules
B7 and CD40 (Pilat et al. 2011).
However, for cytotoxic activity of CD8 positive CTLs intercellular adhesion
molecules like LFA-1, LFA-3, and CD2 have been found to play an important
role (Shaw et al. 1986). Additionally, DNAX accessory molecule-1 (DNAM-1
or CD226) has first been described in the 1990s (Shibuya et al. 1996). It is
an adhesion molecule of the Ig-family, which in mice is expressed on all CD8
T cells, on activated CD4 T cells and a part of the NK cells (Dardalhon et
al. 2005). DNAM-1 ligation is crucial for cytotoxic activity of NK and T cells
against non-classical APCs like tumor cells (Gilfillan et al. 2008; Seth et al.
2009; Tahara-Hanaoka et al. 2006). Also during priming of CD8 T cells by
non-professional APCs like B cells DNAM-1 plays an important role (Gilfillan
et al. 2008).
DNAM-1 has two known ligands CD155 (Necl-5, PVR) and CD112 (nectin-2)
(Fig. 1.5). Both are expressed on a variety of epithelial, endothelial, and anti-
gen presenting cells (Bottino et al. 2003; Gilfillan et al. 2008; Pende et al.
2006; Takai et al. 2008). CD155 has a higher affinity to DNAM-1 then CD112
(Reymond et al. 2004; Seth et al. 2009).
Renal tubular epithelial cells (rTECs) are the major target of allospecific CTLs
during cellular renal allograft rejection. They have been shown to act as non-
professional APCs under inflammatory conditions, as they express MHC I and
II and also the costimulatory molecule CD40 but not CD80 and CD86 (Starke
et al. 2007; Wuthrich et al. 1990).
In this study we therefore investigated the role of DNAM-1 and both of its
ligands for allospecific T cell priming and cytotoxicity against renal tubular
epithelial cells in vitro and in vivo.
Material and Methods
Mice
C57BL/6 (B6, H-2b), CBA (H-2k), and Balb/c (H-2d), DBA/2 (H-2d), and
B6.C-H2-Kbm1/By (bm1, H-2bm1) mice were housed in specific pathogen-free
conditions at the University of Zu¨rich. Bm1 mice express the same H-2 hap-
lotype as B6 (H-2b) except for 7 nucleotide differences in the gene for H-2Kb
Results 63
resulting in amino acid substitutions at codons 152 (glutamate to alanine),
155 (arginine to tyrosine) and 156 (leucine to tyrosine) (Schulze et al. 1983).
CD155 KO mice (H-2d) and CD112 KO mice (H-2b) were kindly provided by
Dr. Gu¨nter Bernhardt (Hannover Medical School). All animal experiments
were performed according to protocols approved by the legal authority (Veteri-
nary Office of the Canton of Zu¨rich).
Culture of renal tubular epithelial cells
Preparation and primary culture of renal tubular epithelial cells was performed
as described (Wuthrich et al. 1990). Cells were cultured on collagen-coated
dishes in K1 media. In all cytotoxicity experiments primary renal tubular ep-
ithelial cells were prestimulated for 48 hours with murine IFN-β and -γ at 100
U/ml each (both purchased from Antigenix America Inc., Huntington Station,
NY, USA), prior to use.
T cell proliferation and cell-mediated lympholysis (CML) assay
T cell proliferation and CML assays were performed using either whole spleen or
isolated CD4 and CD8 positive T cells as responders. T cells were sorted from
whole spleen by magnetic cell separation (MACS) according to the protocols
of Miltenyi Biotec (Bergisch Gladbach, Germany). Purity of sorted cells was
confirmed by FACS analysis. T cells were stimulated with irradiated (30 Gy)
splenocytes from allogeneic and syngeneic mice.
T cell proliferation was measured by incorporation of 3H-labeled thymidine
(Perkin Elmer, Waltham, USA) on day 4 of culture.
CML assays were performed on day 5 of culture: 51Chromium (Cr)-labeled,
IFN-stimulated allogeneic renal tubular epithelial cells were added to the serially
diluted culture for 4 hours (killing phase), and allospecific cytotoxicity was
assessed by measurement of Cr-release in the supernatant. Allospecific lysis
was calculated as:
% specific lysis =
(experimental release − spontaneous release)
(total release − spontaneous release) ∗ 100
In some assays blocking antibodies against mouse DNAM-1 (3B3, Seth et al.
2009) or CD112 (6B3, Aoki et al.) were added to the culture. These and
the matching unspecific isotype control were kindly provided by Dr. Gu¨nter
Bernhardt (Hannover Medical School). Concentrations are indicated.
FACS
FACS was performed with a BD-FACSCanto II (Becton Dickinson, Allschwil,
Switzerland). Anti-mouse CD3-FITC, CD4-PE, CD8-APC, anti rat-IgG-FITC,
and propidium iodide (PI) were purchased from eBioscience (Frankfurt, Ger-
many). Rat anti-mouse CD155 was purchased from Biolegend (Fell, Germany)
and rat anti-mouse CD112 from Santa Cruz Biotechnology (Heidelberg, Ger-
many).
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mRNA isolation and qPCR
mRNA was isolated from kidney grafts or naive kidneys, which had been stored
in RNase-inhibitor, using the RNeasy Mini Kit (Qiagen) according to manu-
facturer’s instructions. 1 µg mRNA was transcribed to cDNA using the Om-
niscript reverse transcription Kit (Qiagen) according to manufacturer’s instruc-
tions. Pre-developed TaqMan reagents were used for quantitative PCR (Applied
Biosystems) detecting murine CD155 and CD112, and the reference 18s rRNA.
The expression of candidate genes was normalized to the reference, and fold
changes were calculated in relation to the matching controls using the 2−ddCt
method.
Skin and kidney grafting
At day 0 full thickness tail skin (about 0.5-1.0 cm2) from donor mice was trans-
planted to the dorsal flank area of recipient mice. Graft rejection was defined
as graft necrosis > 90% of the graft.
Kidney grafts were performed in a non-life-supporting manner as previously
described in detail (Tian et al. 2010). The recipient was unilaterally nephrec-
tomized and orthotopic transplantation was performed on the right side. Allo-
grafts were harvested on day 21.
Histology and immunohistochemistry
Histologic examination of all kidney grafts was performed by an experienced re-
nal pathologist blinded to the experimental procedures. Tissues were immersion-
fixed in 4% phosphate buffered formalin and embedded in paraffin. The thick-
ness of sections was 4 µm. The slides were routinely stained with hematoxylin
and eosin (H & E).
For detection of apoptotic cells by immunohistochemistry the monoclonal anti-
body F7-26 (Chemicon, International, Inc. Temecula, CA) was used as previ-
ously described (Segerer et al. 2002). F7-26 binds to single-stranded DNA after
thermal denaturation. A peroxidase-conjugated monoclonal rat anti-mouse IgM
antibody (Zymed, San Francisco, CA) was used as secondary reagent. Dense,
apoptotic nuclei positive for single stranded DNA were quantified in mouse
renal allografts in 15 high power fields (original magnification ×250).
Statistical analysis
All statistical comparisons were performed with GraphPad Prism 4. Normally
distributed groups were compared using Student’s t test. Groups without Gaus-
sian distribution were compared using the Mann-Whitney test. P < 0.05 was
considered significant.
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Results
Ligands for DNAM-1 are expressed in the kidney and upregulated
in acute allograft rejection
Expression of both ligands for DNAM-1, CD155 and CD112, has been shown
in naive murine kidneys (Nabekura et al. 2010). We tested the regulation of
expression of both molecules in acutely rejected renal allografts. Quantitative
PCR analysis showed an induction of both DNAM-1 ligands compared to naive
kidneys (Fig. 2.13A). This induction was not present in syngeneic control allo-
grafts. The upregulation of CD155 and CD112 correlated with each other (Fig.
2.13B).
RT-PCR of whole organs does not reveal the exact location of expression. To
test whether CD155 and CD112 are expressed on renal epithelium, we stained
for them on primary rTECs. FACS analysis showed a constitutive expression of
both molecules on WT B6 rTECs (Fig. 2.13B). The addition of proinflamma-
tory cytokines like IFN-β and -γ further increased this expression (Fig. 2.13B).
Immunohistochemical staining for CD155 in naive and acutely rejected kidneys
is ongoing.
DNAM-1 blockade in vitro reduces allospecific T cell activation in-
dependently of both ligands
To test for the role of DNAM-1 in allospecific T cell priming, we performed clas-
sical in vitro MLR assays using isolated T cells from CBA mice stimulated with
syngeneic or fully MHC mismatched B6 splenocytes. Either isotype-control or
anti-DNAM-1 antibody was added to the coculture from day 0. Proliferation
was measured by 3H-thymidine incorporation at day 4. Allospecific prolifer-
ation was significantly reduced in all three combinations using CD8 or CD4
T cells alone or both subtypes in combination (Fig. 2.14A). Thus, DNAM-1
signaling is important for both allospecific CD4 and CD8 T cell proliferation.
To identify which ligand of DNAM-1 is important for this effect, we performed
MLR assays using allogeneic stimulators deficient in either CD155 or CD112.
Both T cell subtypes alone or in combination were stimulated with completely
MHC mismatched splenocytes. In none of the cocultures we detected reduction
of allospecific proliferation, when stimulators did not express CD155 or CD112
(Fig. 2.14B and C). And contrary to the previously published results, a lack of
CD155 on stimulators did increase allospecific proliferation significantly, when
CD8 and CD4 T cells were cultured together (Fig. 2.14B). The same was true
for CD112: CD4 T cells responding alone and CD4 and CD8 T cells cultured
together proliferate significantly more if stimulators do not express CD112 (Fig.
2.14C).
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To further test the influence of DNAM-1 on allospecific T cell activation, we
tested the ability of similarly stimulated T cells to kill rTECs from allogeneic
WT donors. Along with the results for proliferation, the cytotoxic activity
against rTECs of T cells stimulated in the presence of a blocking DNAM-1
antibody was reduced (Fig. 2.14D). To test the influence of CD155 and CD112
on T cell priming in this setup, we used T cells stimulated in the presence
or absence of CD155 or CD112 on stimulators. In parallel to the results for
proliferation, cytotoxicity was not significantly altered and by trend higher,
when stimulators did not express CD155 or CD112 (Fig. 2.14E and F).
A
0
1
2
3
4
5
6
7
8
9
* ns
Fo
ld
 c
ha
ng
e 
to
 n
ai
ve
syn allo
CD112
syn allo
CD155
B
0 2.5 5.0 7.5
0
2.5
5.0
7.5
CD112
C
D
15
5
r2 = 0.9741
%
 o
f m
ax
%
 o
f m
ax
CD112
CD155
Fluorescence intensity
C
Figure 2.13: Ligands for DNAM-1 are upregulated in acutely rejected renal allo-
grafts. (A, B) Renal allografts from B6 to fully MHC-mismatched CBA recipients were per-
formed. Allografts were acutely rejected at day 7 post transplantation. As control syngeneic
grafts were used. (n = 5 per group) Real time-PCR for CD155 and CD112 was performed
on naive kidneys and kidney grafts. (A) The fold upregulation of CD112 and CD155 com-
pared to naive renal tissue is depicted. Groups were compared using the Mann-Whitney-test:
*P = 0.0159, ns = not significant. (B) CD112 and CD155 expression are highly correlated.
(C) Primary rTECs were left untreated or stimulated with IFN-β and -γ (100 U/ml each) for
48 hours. Surface expression of CD155 and CD112 was analyzed by FACS. Shaded: isotype
control, dotted line: unstimulated, solid line: stimulated.
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Figure 2.14: DNAM-1 assisted T cell activation is independent of CD155 and
CD112 in vitro. (A) Isolated CBA T cells were stimulated with irradiated B6 splenocytes.
CD8 or CD4 T cells were either cultured alone or in combination (ratio 1:2). To the coculture
an agonistic anti-DNAM-1 antibody was added at 25 µg/ml. As control an unspecific isotype
control antibody was used at the same concentration. Proliferation was measured on d 4 of
coculture. *P < 0.035, **P < 0.01. (B) Isolated B6 T cells were stimulated with irradiated
Balb/c WT or CD155 KO splenocytes. CD8 or CD4 T cells were either cultured alone or
in combination (ratio 1:2). Proliferation was measured on d 4 of coculture. **P = 0.0025.
(C) Isolated CBA T cells were stimulated with irradiated B6 WT or CD112 KO splenocytes.
CD8 or CD4 T cells were either cultured alone or in combination (ratio 1:2). Proliferation
was measured on d 4 of coculture. *P < 0.018 (D) CBA splenocytes were stimulated with
irradiated B6 splenocytes in presence or absence of anti-DNAM-1 antibody (25 µg/ml). Cy-
totoxic activity against IFN-stimulated WT B6 rTECs was measured on d 5. (E) Isolated
CD8 and CD4 T cells (ratio 1:2) were stimulated with irradiated WT Balb/c or CD155 KO
splenocytes. Cytotoxicity against IFN-stimulated WT Balb/c rTECs was measured on d 5
of coculture. (F) CBA splenocytes were stimulated with irradiated B6 or CD112 KO spleno-
cytes. Cytotoxicity against IFN-stimulated WT B6 rTECs was measured on d 5 of coculture.
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Allospecific T cell cytotoxicity against rTECs is independent of DNAM-
1 in vitro
RTECs act as non-professional APCs under inflammatory conditions (Starke et
al. 2007; Wuthrich et al. 1990). We therefore wanted to test the importance of
DNAM-1 signaling in allospecific cytotoxic activity against rTECs during the
effector phase. Therefore, we used allospecifically stimulated splenocytes and
tested their cytotoxic activity against WT and CD155 or CD112 KO rTECs. In
both cases, when taking away one ligand on the target cells, killing rates were
not altered (Fig. 2.15A and B). As there could be redundancy between both
ligands, we used CD155 KO targets and added a blocking antibody against
CD112 during the effector phase. Also, when none of the two ligands was
available for DNAM-1, rTEC killing was not impaired (Fig. 2.15C). Finally, to
exclude the possibility of a third unknown ligand binding to DNAM-1 we added
a blocking antibody against DNAM-1. This also did not reduce allospecific
killing of rTECs (Fig. 2.15D), suggesting that DNAM-1 activity is not essential
for the cytotoxic activity of T cells against rTECs in vitro.
Lack of CD155 or CD112 expression does not prolong allogeneic skin
graft survival
In order to evaluate the role of CD155 and CD112 for allograft rejection in vivo,
we performed skin grafts using grafts from donors deficient in either CD155 or
CD112 on completely MHC mismatched recipients. In both cases, no difference
in the time course of graft rejection could be observed (Fig. 2.17A and C).
To look for more subtle differences we repeated these experiments in a minor-
mismatch and a single-antigen-mismatch situation. For the CD155 KO donors,
we used DBA/2 mice. These mice possess the same haplotype as Balb/c (H-
2d), but have a different background leading to a mismatch in minor antigens.
CD112 KO animals are of B6 background (H-2b). In this case we used bm1
mice as recipients. These animals have a three amino acid exchange in the Kb
molecule, leading to a single-antigen-mismatch compared to WT B6. In both
combinations, no prolongation of skin graft survival was detected, when one of
the two ligands for DNAM-1 was absent on the graft (Fig. 2.16C and D). In
contrast, when CD112 was missing on the allograft, survival was even impaired
(Fig. 2.16D).
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Figure 2.15: Cytotoxic activity of allospecific T cells against rTECs is not DNAM-
1 dependent in vitro. (A) CBA splenocytes were stimulated with irradiated Balb/c spleno-
cytes. Cytotoxicity against IFN-stimulated WT Balb/c or CD155 KO rTEC targets was
measured on d 5 of coculture. (B) CBA splenocytes were stimulated with irradiated B6
splenocytes. Cytotoxicity against IFN-stimulated B6 WT or CD112 KO targets was mea-
sured on d 5 of coculture. (C) CBA splenocytes were stimulated with irradiated Balb/c
splenocytes. Cytotoxicity against IFN-stimulated CD155 KO rTEC targets in the presence
(25 µg/ml) or absence of a blocking anti-CD112 antibody was measured on d 5 of coculture.
(D) CBA splenocytes were stimulated with irradiated B6 splenocytes. Cytotoxicity against
IFN-stimulated WT targets was measured on d 5 of coculture in the presence or absence of a
blocking anti-DNAM-1 antibody (50 µg/ml).
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Figure 2.16: Lack of DNAM-1 ligands does not prolong skin allograft survival. (A)
Skin grafts from fully MHC-mismatched WT Balb/c (n = 19) or CD155 KO (n = 24) donors
were performed on B6 recipients. Median survival time: 9 vs. 10 days (WT vs. CD155 KO).
(B) Skin grafts from WT Balb/c (n = 7) or CD155 KO (n = 8) donors were performed on
DBA/2 recipients. Median survival time: 13 vs. 15 days (WT vs. CD155 KO). (C) Skin grafts
from fully MHC mismatched WT B6 (n = 8) or CD112 KO (n = 8) donors were performed
on CBA recipients. Median survival time: 11 vs. 12 days (WT vs. CD112 KO). (D) Skin
grafts from single antigen mismatched B6 (n = 7) or CD112 (n = 8) donors were performed
on bm1 recipients. Median survival time: 25.5 vs. 21 days (WT vs. CD112 KO), P = 0.0095
in log-rank-test.
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Renal allograft rejection is not dependent on DNAM-1 ligand expres-
sion in the graft
Finally, we explored if expression of either ligand for DNAM-1 has an influence
on renal allograft rejection in vivo. We thus performed kidney allografts in a
completely MHC- mismatched model. For CD155 KO we used the combina-
tion Balb/c to B6 and for CD112 B6 to CBA was used. Renal allografts were
performed in a non-life supporting manner, leaving the left kidney in place and
replacing only the right kidney by the allograft. After 21 days allografts were
harvested. All allografts showed severe infiltrates in the interstitium indepen-
dent of expression of CD155 or CD112. After 21 days the renal parenchyma
showed intense interstitial infiltrates, important tubulitis, endothlitis, and tis-
siue destruction in all allografts (Fig. 2.17A-B, D-E).
Interstingly, we observed a higher incidence of infarcts and subsequent devel-
opment necrosis in allografts lacking CD155 or CD112. The exact reason for
this finding is still to be elucidated.
We also assessed the amount of apoptotic epithelial cells in all allografts, as an
indirect measure of cytotoxic activity in vivo. Also for this parameter we could
not detect any difference when comparing CD155 or CD112 KO allografts with
the matching WT controls, confirming our in vitro results (Fig. 2.17C and F).
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Figure 2.17: Kidney grafts. (A-C) Balb/c WT or CD155 KO mice were used as donors
for non-life-supporting kidney grafts to B6 recipients. Organs were harvested after 21days
(n = 5 per group). (A, B) Representative hematoxylin and eosin stain showing interstitial
infiltrates and parenchymal destruction in WT (A) and CD155 KO (B) allografts. (D-F)
B6 WT (n = 4) or CD112 KO (n = 3) mice were used as donors for non-life-supporting
kidney grafts to CBA recipients. Organs were harvested after 21days. (D, E) Representative
hematoxylin and eosin stain showing interstitial infiltrates and parenchymal destruction in WT
(D) and CD112 KO (E) allografts. (C, F) Immunohistochemistry for ssDNA was performed
on all grafts. Quantitative analysis is depicted.
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Discussion
In this study we evaluated the role of DNAM-1 and its ligand for allospecific T
cell activation in in vitro and in vivo. We found that DNAM-1 signaling played
a role during the priming of directly alloreactive T cells in vitro. However, this
process was independent of the two known ligands of DNAM-1, CD155 and
CD112. Furthermore, we could not detect a role for DNAM-1 signaling during
the effector function of cytolysis of rTECs mediated by allospecific T cells. Us-
ing two in vivo models for allograft rejection, skin and renal allografts, these in
vitro results were confirmed. The time course of skin allograft rejection was not
altered, depending on the expression of CD155 or CD112. Also the severity of
cellular rejection in renal allografts from CD155 or CD112 KO donors was sim-
ilar to that in WT grafts. However, in renal allografts from CD155 or CD112
KO donors a higher incidence of infarcts was detected.
Expression of CD155 and CD112 in murine kidneys has previously been shown
(Nabekura et al. 2010). Both molecules are expressed on epithelial and en-
dothelial cells (Takai et al. 2008). Here we show that CD155 and CD112
were upregulated in acutely rejected renal allografts. The exact site of expres-
sion cannot be identified by qPCR. Immunohistochemical staining is currently
performed. However, we found expression of CD155 and CD112 on primary
rTECs, which was increased under inflammatory conditions, indicating expres-
sion of the two molecules to the tubular compartment of the kidney.
In several in vitro models it was shown, that the expression of CD155 or CD112
facilitates the DNAM-1 mediated cytotoxic activity of NK and T cells against
tumor cells (Shibuya et al. 1996; Tahara-Hanaoka et al. 2006) or autologous
DCs (Pende et al. 2006; Seth et al. 2009). This is also represented by the lower
ability of DNAM-1 deficient mice to reject tumors (Iguchi-Manaka et al. 2008).
Furthermore, Gilfillan et al. postulated a role of DNAM-1/CD155 interaction
for the cytotoxic activity of T cells against non-professional APCs (Gilfillan et
al. 2008). We thus hypothesized that the interaction of T cells with rTECs,
which are capable of acting as non-professional APCs and do express both
CD155 and CD112, might also be dependent on DNAM-1 interactions with its
ligands. However, we could not detect any role for DNAM-1 ligation by CD155
or CD112 for cytotoxic activity against allogeneic rTECs in vitro and in vivo.
In the study of Gilfillan et al. it was also shown that OVA-specific DNAM-
1 expressing CD8 T cells proliferated more when stimulated with an OVA-
pulsed, CD155 transformed T cell lymphoma cell line (EL-4), compared to their
DNAM-1 KO counterparts (Gilfillan et al. 2008). Consistent with this we saw
reduced proliferation and subsequent lower cytotoxic activity against rTECs,
when DNAM-1 was blocked during the stimulation of T cells. However, this
observation was completely independent of the expression of DNAM-1 ligands
on the stimulator or target cells. Furthermore, DNAM-1 was dispensable for
cytotoxic activity against rTECs of fully activated allospecific T cells. This
suggests a role for DNAM-1 signaling during T cell priming, and not during
the process of cytolysis in this in vitro model of alloreactivity. Moreover, this
signaling was independent of interaction of DNAM-1 with CD155 or CD112,
indicating another role for DNAM-1 in T cell priming. In line with this Shibuya
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et al. showed that DNAM-1 signaling is involved in the LFA-1 mediated T cell
activation (Shibuya et al. 2003). The authors induced T cell proliferation and
differentiation by stimulating CD3 and LFA-1 and showed that this process is
dependent on DNAM-1 signaling. In these experiments functional DNAM-1
was crucial for T cell activation - completely independent of ligand interaction
and only dependent on the interaction with LFA-1 and phosphorylation of ty-
rosine 322 in DNAM-1 (Shibuya et al. 2003). Direct interaction of DNAM-1
and LFA-1 was proven by co-precipitation experiments (Shibuya et al. 2003).
In a previous report it was postulated that a role for DNAM-1 signaling for
the activation of T cells by professional APCs like DCs can be excluded (Gil-
fillan et al. 2008). However, in our in vitro model T cells are mainly activated
by DCs (Kraus et al., submitted manuscript). The first interaction of T cells
with DCs is mediated by LFA-1 binding to ICAM-1 (Ford and Larsen 2009).
The blockade of DNAM-1 with an antibody might prevent close interaction of
DNAM-1 and LFA-1 and thus prevent the costimulatory signal, which is medi-
ated by LFA-1. Moreover, the bound antibody might lead to a steric inhibition
of the T cell-APC contact at the site of LFA-1/ICAM-1 interaction and thereby
impair efficient T cell priming.
When using CD155 or CD112 deficient cells as stimulators in in vitro prolif-
eration and cytotoxicity assays, we could not detect reduced T cell activation.
In contrast, T cell effector functions were, if at all different to the WT control,
rather increased. This effect was the same for CD4 and CD8 T cells and also,
when they were cocultured. This observation indicated a regulatory role of
CD155 and CD112 during the process of T cell priming. Indeed, it has been
shown that CD155 on human vascular endothelial cells attenuates the acquisi-
tion of effector functions in CD8 T cells (Escalante et al. 2011). Furthermore,
another receptor for CD155 was recently identified to be expressed on CD4 T
cells: TIGIT binds to CD155 and thereby reduces naive human CD4 T cell
activation (Yu et al. 2009). Finally, CD155 KO mice have been shown to be
more susceptible to graft-versus-host disease in a CD4 T cell-dependent model
(Seth et al. 2011). The exact mechanisms for this phenomenon have still to be
elucidated.
A recent study demonstrated that DNAM-1 blockade or deficiency on T cells
reduced graft-versus-host disease in a CD8 T cell-dependent model (Nabekura
et al. 2010). We thus wanted to test the role of the two DNAM-1 ligands in
solid allograft rejection. Therefore we used two different models. Skin graft-
ing is the most stringent model for allograft rejection. In this setup, we could
not show an influence for any of the two known DNAM-1 ligands. This was
true for both, major- and minor-mismatch models. For CD155 we also showed
that it is dispensable for both the priming and the effector phase (data not
shown). We further tested our findings in a completely MHC mismatched renal
allograft model. DNAM-1-CD155 interaction is crucial for the diapedesis step
during monocyte extravasation in a model using a human endothelial cell line
(Reymond et al. 2004). One would therefore suspect to find a lower amount
of infiltrating cells in renal allografts from CD155 KO donors. We could not
detect such an effect. WT and CD155 KO allografts showed similar amounts
of cellular infiltrates in the interstitium, and the same was true for CD112 KO
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allografts. This finding goes along with the report of Seth et al., who could not
detect differences in infiltrates in the intestine after induction of graft-versus-
host-disease in CD155 KO animals (Seth et al. 2011). We found that the same
is also true for CD112 KO kidney allografts.
DNAM-1 mediates platelet adhesion to vascular endothelial cells (Kojima et al.
2003). One could therefore speculate that binding of platelets to endothelium
lacking CD155 or CD112 might be reduced. However, one difference that we
found between renal allografts from WT donors and those deficient in CD155
or CD112 was a higher incidence of infarcts, when one of the two molecules was
missing. Taking into account the pivotal role, which nectin and necl proteins
play for cell-cell adhesion, a less intact endothelium might be the reason for
more thrombosis. CD155 is located on the leading edge of moving cells and
mediates signaling to inhibit proliferation upon cell-cell-contact (Takai et al.
2008). CD112 together with other nectin proteins builds first cell-cell adhesion
connections before cadherins (Takai et al. 2008). Ischemia-reperfusion injury
causes endothelial damage (Harris et al. 1996), which might be repaired less
efficiently in renal allografts from CD155 and CD112 KO donors. Gaps in the
endothelium might then reveal the subendothelial layer and allow platelet acti-
vation and adhesion leading to clotting of the vessel (Wagner and Burger 2003).
This hypothesis needs further investigation.
Taken together our results suggest a beneficial effect in solid allograft rejection
for DNAM-1 blockade by reducing T cell priming. The blockade of either one of
its ligands, however, does not seem favorable due to increased T cell activity in
vitro, no effect on renal allograft rejection, and higher incidence of thrombosis.
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The role of CD40-CD154 during allospecific CD8 T
cell priming
The classical model for CD4-dependent CD8 T cell activation includes the inter-
action of both the CD4 and the CD8 T cell with the same APC. The CD4 T cell
interacts with the DC via CD154-CD40 and thereby enables cross-presenting of
antigens and higher expression of costimulatory molecules like B7 (Banchereau
and Steinman 1998). Such a maturated DC is then able to efficiently prime CD8
T cells (Fig. 3.1). The CD4 T cell on the other hand is enabled to produce
cytokines like IL-2, which gives a survival signal to the CD8 T cell. That this
model is true also for alloresponses is supported by the finding, that triggering
of CD40 can replace CD4 help in a murine model for heart transplantation
(Fischbein et al. 2000), meaning that the sole need for CD8 activation is a DC
matured due to CD40 ligation. Shepherd et al. however used a model, in which
the allospecific clearance of injected P815 cells was not restored by exogenous
CD40 triggering in CD154 deficient mice. They furthermore could show that
APCs in CD154-deficient mice did not show signs of reduced activation. This
suggests, that the lack of CD154 on T cells disables acquisition of T cell effec-
tor function, even though DCs would be well able to induce it. In our in vitro
studies we also could not detect a difference between WT and CD40 KO DCs
in MHC class II and B7 molecule expression after coculture with allogeneic T
cells (data not shown). Thus, the defect in cytotoxic T cell priming, which we
observed in vitro when APCs did not express CD40, is not due to reduced DC
maturation, but to a lack in CD154 signaling to the T cell itself.
A direct interaction of CD154 on CD8 T cells and CD40 on the DC is not
included in the classical model of CD40-mediated DC maturation and T cell
priming (Fig. 3.1). However, CD154 is expressed on CD8 T cells (Hermann et
al. 1995; Sad et al. 1997). When using a skin graft model, which is mainly re-
stricted to the response of directly alloreactive CD8 T cells due to a single MHC
class I mismatch, we detected prolongation of skin graft survival, if the donor
did not express CD40. This indicates that also CD4- independent CD8 T cells
need a costimulatory signal via CD154. It is known that CD154-deficient mice
mount reduced allospecific immune responses (Buhlmann and Noelle 1996; Zhai
et al. 2002). However, in these models a deficient CD4 T cell help cannot be
ruled out as reason. Other group’s results support our findings by using CD4-
depleted recipients for completely MHC-mismatched skin allografts. Blocking
CD154 with an antibody in this model prevented CD4 T cell-independent CD8
activation (Zhai et al. 2003). It has furthermore been shown that CD4 T help-
independent clearance of allogeneic cells happened, when injected P815 cells
were expressing B7-2. Injecting such cells in CD154 deficient animals however
did not lead to generation of allospecific CD8 positive CTLs. This could also
not be restored by maturating host DCs by exogenous triggering of the CD40
pathway (Shepherd and Kerkvliet 1999). This suggests, along with our results,
that a direct interaction of CD8-CD154 and APC-CD40 is necessary for allore-
activity. In contrast, there are reports claiming, that allospecific CD8 T cells
are not sensitive to CD154 blockade and still are able to reject skin allografts
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independently of CD40-CD154 signaling (Jones et al. 2000). However, they
were at least partially performed with T cell receptor transgenic CD8 T cells
from BM3.3 mice, which are easy to activate and do not depend on CD8 bind-
ing. We have used these cells in in vitro experiments and found that they are,
in contrast to WT T cells, not CD40-dependent (data not shown).
Moreover, we could show in vitro for the first time that directly allospecific
CD8 T cells need a direct signal via CD154 to achieve full activation, even in
the presence of intact CD4 help (Fig. 3.1). This result has still to be proven in
vivo.
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Figure 3.1: Models for CD8 T cell priming
(A) The classical model for CD4 dependent CD8 T cell activation includes the contact of CD4
and CD8 T cell with the same DC: (1.) Contact via CD154 on the CD4 T cell and CD40
on the APC enables the DC to express additional B7 molecules and to cross-present (2.).
The CD4 T cell is enabled to produce IL-2, which gives a survival signal to the CD8 T cell
(2.). Thus, a fully activated effector CD8 T cell is generated (3.). (B) In the absence of CD4
help, allospecific CD8 T cells need additionally to the B7-CD28 interaction a direct signal via
CD154 in order to become potent effector cells. (C) Our in vitro results also support this
third model, in which CD8 T cells are dependent on a direct interaction with the APC via
CD154 in order to become completely activated, when CD4 help is intact.
Is Blockade of CD40 instead of CD154 as efficient?
Blockade of the CD40-CD154 pathway has so far mainly been performed by
blocking CD154 with antibodies. The mechanism of immunosuppression ob-
served with such agents is still not completely elucidated. While blocking
CD154 might just be a way to block a costimulatory signal to the T cell, it
has also been proposed that it leads to T cell apoptosis (Blair et al. 2000) or
depletion (Monk et al. 2003). Therefore the ability of CD40-blockade to repro-
duce the same effects of CD154-blockade is questioned. There are some studies
targeting CD40 for immunosuppression or tolerance induction in transplanta-
tion models in non-human primates. However, most of the antibodies used so
far have shown at least partially B cell depleting properties (Adams et al. 2005;
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Aoyagi et al. 2009; Pearson et al. 2002; t Hart et al. 2005). One of these anti-
bodies (4D11, ASKP1240) is now in Phase II studies for kidney transplantation
(Pilat et al. 2011). Just recently, two studies using a non-depleting anti-CD40
antibody were published. 3A8 is a completely murine antibody, which is able
to block costimulatory signals to allospecific T cells, however still allows bind-
ing of soluble CD154 and induces B7 upregulation on B cells (Badell et al.
2012). It was able to prolong islet allograft survival and assist in induction of
mixed chimerism combined with CTLA4-Ig and an mTOR inhibitor (Badell et
al. 2012; Page et al. 2012). In recipients of islet transplants 3A8 was further-
more able to prevent development of allospecific antibodies. Even though these
results are promising the potential immunogenicity of a fully murine antibody
seems to hamper its in vivo efficacy (Badell et al. 2012).
Currently, there is no antibody against murine CD40 with similar properties.
For mechanistic studies to elucidate the role of CD40 blockade compared to
CD154-blockade such a tool would be very useful. In this study we therefore
developed an F(ab)-fragment directed against murine CD40, which has shown
potent inhibitory properties in vitro by inhibiting CD40-triggered B cell acti-
vation and proliferation and also allospecific T cell proliferation and cytokine
production. The direct comparison between F(ab)86 and CD154-blockade still
has to be made in vitro and in vivo. F(ab)86 has to be modified to increase
half-life in order to be used in vivo. The strategies to do so are discussed in
section 2 of the results chapter. Using an F(ab)-fragment, which is pegylated
or fused to a larger protein like α1-antitrypsin, we also expect lower immuno-
genicity and a lower risk of adverse events usually linked to use of therapeutic
antibodies in humans.
Which role do Th17 cells play in renal allograft rejec-
tion?
In vitro we found a strong dependency of allospecific Th17 induction on the
costimulatory molecule CD40 expressed on the stimulator cells. This finding is
supported by observations made by Iezzi et al. (Iezzi et al. 2009). They showed
complete abolishment of Th17 induction in EAE using CD40-deficient mice.
Thus, the use of costimulation blockade directed against the CD40 pathway
might reduce the induction of the Th17 T cell subset, which has been shown to
have deleterious effects in autoimmune diseases (Hu et al. 2010). However, the
role of Th17 cells in allotransplantation is still under investigation. There are
studies indicating a role for IL-17A in CD4-mediated graft-versus-host disease
(Kappel et al. 2009) and in early allograft inflammation in a cardiac allograft
model (Gorbacheva et al. 2010). Furthermore, increased IL-17 mRNA levels
have been found early in human and rat acute renal allograft rejection (Loong
et al. 2002).
The most convincing studies showing that IL-17-producing T cells can cause
allograft rejection were performed in mice lacking the Th1-specific transcription
factor T-bet (Burrell et al. 2008; Yuan et al. 2008). T-bet knock-out mice are
resistant to costimulation blockade-induced tolerance. In one model this has
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been shown to be due to IL-17 producing CD8 T cells (T17), which are po-
larized under similar conditions as Th17 cells. Blockade of IL-17 concomitant
with costimulation blockade was able to induce long term survival of cardiac
allografts (Burrell et al. 2008). Also blockade of TIM-1, which is expressed
on T17 cells, could abrogate the otherwise costimulation-resistant alloresponse
(Yuan et al. 2009). However, it remains unclear whether the processes observed
in these studies are also taking place in animals sufficient in Th1 responses -
especially because CD154-blockade induced allograft tolerance has been shown
to be dependent on IFN-γ in a mouse model for cardiac transplantation. IFN-γ
knock-out mice showed lower Treg activity in the allograft represented by lower
intragraft FoxP3 and IL-10 expression (Jiang et al. 2010).
When searching for IL-17A expression in acutely rejecting renal allografts, we
detected only very low amounts. This may be explained by various reasons:
First Iezzi et al. have shown that the induction of Th17 responses is dependent
on antigen dose and toll-like receptor (TLR) triggering (Iezzi et al. 2009). In
our kidney allograft model the amount of donor APCs migrating to the drain-
ing lymph node may be rather low in comparison to the amount of APCs in
an in vitro MLR. Furthermore, the APCs in the in vitro MLR are irradiated
and thus might receive a danger signal similar to triggering a TLR. Indeed,
TLR-triggering simultaneously with cardiac transplantation is able to abrogate
CD154-blockade induced allograft tolerance and induce rejection. This process
has been shown to be dependent on IL-6 and IL-17 (Chen et al. 2009). In
allografts undergoing rejection IFN-γ- and IL-17-producing CD4 T cells were
found (Chen et al. 2009). We however did not add a TLR stimulus in our renal
allograft model.
Second, it has been found in an in vitro study that human rTECs do not secrete
MIP-3 under inflammatory conditions, a chemokine crucial for the recruitment
of Th17 cells (Demmers et al. 2011). Thus, a low recruitment of Th17 cells
to murine renal allografts could explain the rather low mRNA expression of
IL-17A.
Third, Loong et al. detected IL-17 producing mononuclear cells in renal allo-
grafts as early as day 2 after transplantation (Loong et al. 2002). Since we
harvested the renal allografts only at day 7, this time point might be too late
to detect these effects. In fact, it has been shown that early Th17 migration
into the lung is needed for subsequent Th1 accumulation in a murine model
for tuberculosis (Khader et al. 2007). Furthermore, stimulation with IL-17A
has been shown to induce chemokine production by rTECs (Woltman et al.
2000), which may trigger Th1 recruitment to the transplanted organ (Fig. 3.2)
(Turner et al. 2001). Interestingly, it has been shown that the Th17 lineage is
not completely committed. IFN-γ IL-17A double producers have been detected
in the inflamed CNS (Damsker et al. 2010). Furthermore, Th17 cells can be
converted to Th1 cells in vitro and in vivo (Damsker et al. 2010; Hirota et al.
2011). Th1 cells on the other hand do not seem to be that promiscuous and
seem rather stable in their phenotype (Damsker et al. 2010). Considering this,
it might also be possible that the Th17 cells needed for subsequent Th1 recruit-
ment to the organ, already resemble part of these Th1 cells as they convert
after time (Fig. 3.2).
Discussion 80
IL-17
IL-17
IL-17
IL-17
RANTES, MIP-1
IFN-γ
IFN-γ
IFN-γ
1.
2.
3.
4.
4.
? ?
IFN-γ
Th1
Th17
IL-17 IFN-γ double producer
rTEC in naive state
rTEC in costimulatory state
Figure 3.2: Early Th17 invasion into the renal allograft might be needed to enable
subsequent Th1 infiltration. In this model Th17 cells are the first Th cells to encounter
the allograft (1.). IL-17A production stimulates rTECs to produce chemokines (2.) that in
turn facitlitate the recruitment of Th1 cells (3.) IFN-γ produced by Th1 cell together with IL-
17 from Th17 cells leads to conversion of rTECs to a rather costimulatory surface expression
pattern by downregulation of PD-L1 and upregulation of CD40 (4.). It might be possible that
Th17 cells might convert to Th1 T cells over time via a state of IL-17 IFN-γ double production
and thereby add to or resemble the pool of Th1 cells later present in the graft.
We also examined the response of rTEC surface expression induced by IL-17A
stimulation. When stimulating rTECs with IL-17A alone, we did not detect any
difference in surface marker expression (data not shown). However, an effect
that may play a relevant role during renal allograft rejection was seen, when
IL-17A was combined with IFN-γ. The two cytokines in combination induced
a significant downregulation of the coinhibitory ligand PD-L1, which has been
shown to protect human rTECs from allospecific CTL activity (Starke et al.
2010). On the other hand the expression of the costimulatory molecule CD40
was induced under the influence of both cytokines. This surface expression
pattern makes rTECs even more attractive targets for allospecific T cell activity.
Thus, the early involvement of IL-17 in renal allografts might play a role for
rTEC modulation in the presence of a concomitant Th1 response, which does
not take place in T-bet deficient animals.
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Other costimulation pathways play a role in solid or-
gan allograft rejection
Apart from the CD40-CD154 pathway the other costimulatory pathways play a
variable role in induction of allograft rejection or allograft tolerance. The best
characterized costimulatory pathway is the one mediated by CD28. Its ligation
by the B7 molecules triggers IL-2 production and CD25 expression. The sub-
sequent binding of IL-2 to CD25 triggers the mammalian target of rapamycin
(mTOR), the target of some immunosuppressive drugs (Halloran 2004). The
B7-molecules, however, also bind to the coinhibitory receptor CTLA-4 with
a much higher affinity than CD28 (Linsley et al. 1994). A fusion protein
of CTLA-4 and the Fc region of IgG1 (CTLA-4-Ig) was developed in order to
block CD28 signaling (Linsley et al. 1992). CTLA-4-Ig has been used in several
rodent models for solid organ transplantation. It induces long-term allograft
acceptance of heart (Baliga et al. 1994; Turka et al. 1992), islet (Lenschow et
al. 1992), and renal allografts (Azuma et al. 1996). Despite these strong effects,
CTLA-4-Ig is not able to prevent completely MHC-mismatched skin graft re-
jection (Larsen et al. 1996). Also the translation of CTLA-4-Ig into non-human
primates only leads to modest prolongation of survival of renal and islet allo-
grafts (Kirk et al. 1997; Levisetti et al. 1997). The CTLA-4-Ig molecule has
been further developed to increase affinity to B7-1 and B7-2 and is now used
in clinics as belatacept for maintenance treatment in renal transplant patients
(Vincenti et al. 2010; Vincenti et al. 2005).
CTLA-4 is a coinhibitory receptor expressed on activated T cells and down-
regulates T cell responses (Walunas et al. 1994). Furthermore, CTLA-4 is con-
stitutively expressed on Tregs and is critical for their suppressor function (Wing
et al. 2008). Administration of CTLA-4-Ig prevents binding of B7 molecules
to CTLA-4 expressing T cells. Moreover, it has recently been shown, that
PD-L1 also binds to B7-1, and thereby suppresses T cell proliferation (Butte
et al. 2007). Masking B7-1 with CTLA-4-Ig prevents also this interaction.
Therefore, efforts are still made for developing a CD28-specific blockade, despite
catastrophic results obtained for an anti-CD28 antibody in a phase I trial (Sun-
tharalingam et al. 2006). Patients suffered from a massive cytokine storm upon
administration of this antibody. To prevent this, monovalent molecules against
CD28 are now developed. A single chain Fv construct with α1-antitrypsin di-
rected against CD28 has been shown to prevent allospecific T cell activation in
vitro (Vanhove et al. 2003) and to prevent renal and heart allograft rejection
in combination with a calcineurin inhibitor in non-human primates (Poirier et
al. 2010). Together with blockade of the CD40 pathway however, CTLA-4-Ig
is able to induce long term allograft acceptance in a heart allograft model in
mouse (Larsen et al. 1996), emphasizing the importance of these two costimu-
lation pathways for allospecific immune responses.
However, in CD28-CD154 double knock-out mice complete MHC mismatched
skin allografts are still rejected (Demirci et al. 2004). This rejection has been
shown to be dependent on the OX40 costimulatory pathway. OX40 is expressed
on activated T cells, preferentially on CD4 T cells (Gramaglia et al. 1998). Its
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ligand OX40L is expressed on activated DC, B cells and vascular endothelial
cells (Stuber and Strober 1996). The OX40/OX40L interaction is very im-
portant for the induction of T cell-dependent humoral responses (Stuber and
Strober 1996). OX40 blockade alone is not very efficient in prolonging allograft
survival (Pilat et al. 2011) and has little effect on primary T cell responses
(Demirci et al. 2004). However, OX40-ligation is important for the generation
of memory T cells and the survival of activated memory T cells (Dawicki et al.
2004).
Another costimulatory pathway, whose blockade is beneficial in solid organ
transplantation, is the ICOS/ICOS-L pathway. ICOS is expressed upon acti-
vation on CD8 and CD4 T cells and persists on effector and memory T cells.
ICOS blockade alone does prolong cardiac allograft survival to a lesser degree
than antibodies against CD154 or CTLA4-Ig. However, when combined with
either of them it leads to long term acceptance of cardiac allografts and prevents
acute and chronic rejection (Ozkaynak et al. 2001). This is interesting, because
chronic rejection still takes place in CD154 deficient animals (Shimizu et al.
2000). Furthermore, it has been shown that ICOS stimulation does maintain
late CD154 expression on T cells (Kaminski et al. 2009).
The 4-1BB pathway is also associated with the CD40 pathway. 4-1BB is ex-
pressed on activated T cells, NK cells and DCs and its ligand 4-1BBL on DCs,
macrophages, and B cells (Wang et al. 2003). The engagement of 4-1BB has
been shown to be more important for CD8 activity than for CD4 T cells (Wang
et al. 2003). The link to CD40 signaling has been found in a model system for
CD8-dependent tumor rejection. Mice challenged with tumor cells were able to
reject those, when 4-1BB was activated with an agonistic antibody. However,
this was completely abolished in CD40 deficient mice (Miller et al. 2002). In-
deed, CD40 ligation leads to the expression of 4-1BBL on DCs (Futagawa et al.
2002). Thus, CD40 signaling may be needed to induce complete activation of
CD8 T cells via the 4-1BB pathway. In a model for intestinal transplantation
it was shown that blockade of 4-1BB was able to prevent CD8 T cell-mediated
rejection (Wang et al. 2003). Interestingly, 4-1BB blockade did not prevent
allospecific CD8 T cell proliferation but reduced IFN-γ and TNF-α production
in recipient spleens, indicating that 4-1BB signaling is not necessary for CD8
priming, but rather for the acquisition of effector function.
Finally, cell adhesion molecules have been shown to act as costimulatory re-
ceptors. LFA-1 expressed on T cells is such a molecule. It is crucial for T cell
trafficking but also for the formation of the immunologic synapse between the
APC and the T cell (Nicolls and Gill 2006). Furthermore, it is able to trans-
duce positive signals to the T cell. This has been shown to be dependent on
DNAM-1 (Shibuya et al. 2003). DNAM-1 is another cell-adhesion molecule,
which has been shown to deliver costimulatory signals in T and NK cells. Its
importance for immune responses against tumors mediated by NK cells but
also CTLs is studied in greater detail than its role in alloimmunity. It has
however been shown, that blocking DNAM-1 in a graft-versus-host model is
beneficial (Nabekura et al. 2010). Similar results have been found for LFA-1
blockade alone and even stronger in combination with CD28 blockade (Blazar
et al. 1995). In murine models for solid organ transplantation LFA-1 blockade
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synergized with other costimulation blockers to induce long-term allograft sur-
vival of islets and cardiac allografts and even of immunologically challenging
skin allografts (Pilat et al. 2011). The mechanisms how LFA-1 blockade pro-
longs allograft survival are not completely clear yet. It is likely though, that the
effect is mediated by blockade of the costimulatory signal delivered by LFA-1
and not so much by blockade of T cell trafficking (Ford and Larsen 2009). It
needs to be further investigated, to which degree LFA-1 and DNAM-1 signaling
pathways are interdependent. It has been suggested that DNAM-1 signaling
induced by ligand binding requires additional LFA-1 signals in T cells, which
are not completely activated yet (Tahara-Hanaoka et al. 2004).
Furthermore, it is not completely clear which role the ligands of DNAM-1 play
in alloresponses. The two molecules are constitutively expressed on many cell
types and important for cell-cell adhesion (Takai et al. 2008). We found that
DNAM-1 blockade reduces allospecific T cell priming independent of the two
ligands for DNAM-1. In contrast, we found rather higher induction of allore-
sponses, when the stimulating cells were lacking CD155 or CD112 - a finding
consistent with enhanced graft-versus-host diesease in CD155 KO recipients
(Seth et al. 2011). Moreover, when we transplanted kidneys from CD155 or
CD112 donors, we observed a higher incidence of thromboembolic events, indi-
cating a less stable vascular endothelium in these kidneys. Research conducted
to reduce allospecific response to solid organ transplants will thus rather have
to focus on DNAM-1 in combination with LFA-1 and most probably not on the
ligands for DNAM-1.
Costimulatory molecules expressed on rTECs
With this work we could offer a more detailed insight in the interaction of host
T cells with donor APCs and rTECs via two costimulatory molecules. Inter-
estingly, we could not detect a major influence of CD40, CD155, or CD112
expressed on rTECs on the activity of allospecific T cells, as it has been shown
for the coinhibitory molecule PD-L1 (Starke et al. 2010).
For the ligation of CD40 on rTECs it is described, that rTECs increase chemokine
production (Woltman et al. 2000). It would thus be interesting to investigate
the results of CD40 ligation on rTECs for the microenviroment of a renal allo-
graft in more detail. We found better renal function in allografts which did not
express CD40. So far we linked this to a difference in the cytokine millieu in
the allograft and subsequent alterations of rTEC surface expression. However,
there might still be an additional regulatory influence of CD40 signaling in the
rTEC, which we were not able to detect with the methods we used. Considering
the much higher expression of CD40 on human rTECs (Demmers et al. 2011)
the influence of rTEC-CD40 on the interaction with T cells might also differ
greatly compared to the murine model system. In this context, blocking CD40
might be beneficial for protection of the renal allograft beyond inhibiting T cell
responses, and in this respect also be an advantage over CD154 blockade.
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About the importance of CD155 and CD112, the two ligands for DNAM-1, ex-
pressed on rTECs not much is known apart from their cell-cell-adhesion proper-
ties. We could not detect an immune-regulatory function of these two molecules
expressed on rTECs in this work. However, CD155 expression on human en-
dothelial cells has been shown to have an influence on the activation of CD8
T cells by these cells (Escalante et al. 2011). rTECs can also act as non-
professional APCs. However, we were not able to induce T cell proliferation by
stimulation with allogeneic rTECs, which is most probably due to the high PD-
L1 expression induced by inflammatory stimuli. Thus, we were unfortunately
not able to reproduce these results. During priming by professional APCs,
however, CD40 and DNAM-1 play important roles. CD40 expressed on donor
APCs is crucial for complete activation of directly alloreactive T cells including
Th17, Th1 and CTLs.
Another costimulatory molecule expressed on rTECs is ICOS-L (Starke et al.
2007). Not much is known about its role for modulation of intrarenal immune
responses. It has been suggested that ICOS-L on rTECs induces IL-10 secre-
tion in infiltrating T cells (De Haij et al. 2005). Blockade of ICOS in a renal
allograft model sustained the inflammatory response in the kidney and led to
increased tissue damage (Lutz et al. 2007). These studies indicate that ICOS-
L on rTECs rather mediates a downregulation of the immune responses in the
kidney.
ICAM-1, the major ligand for LFA-1, is expressed on rTECs and upregulated
under inflammatory conditions (Wuthrich et al. 1990). Lack of allograft ICAM-
1 prolonges heart allograft survival. However, parallel to our results concerning
DNAM-1, ICAM-1 expression was more imprtant on passenger APCs to induce
T cell priming, not on the organ itself (Zhang et al. 2003).
Taking into account the variety of costimulatory and -inhibitory molecules ex-
pressed on rTECs and their different regulation, more research is needed in or-
der to explore the way rTECs modulate the local intra-graft immune response
during renal allograft rejection.
Memory T cells - a hurdle in solid organ transplanta-
tion
A state of donor specific tolerance in mouse models is nowadays easily achieved
by induction of mixed hematopoetic chimerism via donor bone marrow trans-
plantation under costimulatory blockade (mainly CD154 blockade) (Fehr et al.
2005; Wekerle et al. 1999). However, translation of these models into non-
human primates led to prolonged allograft survival and reduction of alloimmu-
nity, but failed to induce consistent tolerance (Ochiai et al. 2007). Memory
T cells have been found to be a major obstacle for tolerance induction in non-
human primates (Nadazdin et al. 2011). The composition of the T cell reper-
toire differs greatly between a laboratory mouse and a primate. Naive mice
held under pathogen free conditions usually possess about 4 to 8% memory T
cells whereas the T cell repertoire in an adult primate or human is composed
of nearly 50% memory cells (Nadazdin et al. 2011). This memory T cell pool
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also contains allospecific cells. The most obvious way to develop memory T
cells specific for alloantigens is previous exposure to the antigen by pregnancy,
blood transfusion, or previous transplantation (Bingaman and Farber 2004). In
a murine model it has for example been shown that transfused platelets, which
are not expressing MHC, can induce memory T cells against minor antigens
that are able to reject subsequent bone marrow transplants (Patel et al. 2009).
However, even persons who have never received a transplant before can show
allospecific memory (Ford and Larsen 2011). The exposure to environmental
pathogens has been shown to produce cross-reactive memory T cells, which
are able to recognize foreign MHC molecules (Burrows et al. 1995; Panten-
burg et al. 2002). For example T cells specific for Epstein-Barr virus nuclear
antigen-3A in the context of HLA-B8 have been shown to also recognize HLA-
B44 (McDonald et al. 2009). In fact, 45% of virus-specific T cell clones have
been shown to be cross-reactive with at least one allogeneic MHC molecule
(Amir et al. 2010). Interestingly, the frequency of alloreactive T cells is the
same in all T cell compartments (naive, central memory, effector memory, and
terminal effector memory) (Macedo et al. 2009). The difference between a
primary and a memory response thus is not due to different frequencies but
different qualities between naive and memory T cells (Ford and Larsen 2010).
Memory T cells are relatively resistant to calcineurin inhibition and costimu-
latory blockade (Nadazdin et al. 2011) but also to depleting therapies (Pearl
et al. 2005) and regulation (Yang et al. 2007). Thus, T memory cells are not
only an obstacle for tolerance induction but also for long term allograft survival
under immunosuppression. However, the ability of memory T cells to induce
allograft rejection depends on the degree and duration of antigen exposure, con-
text of antigen presentation, and type of pathogen infection (Ford and Larsen
2011). Furthermore, the affinity of the TCR expressed on the memory T cell
to an allo-antigen might determine the possibility to tolerize the cell (Ford and
Larsen 2011). It has been shown that the frequency of donor-specific memory T
cells correlates with allograft outcome in a non-human primate model for renal
transplantation in combination with induction of mixed chimerism (Nadazdin
et al. 2011).
One option to avoid the barrier formed by donor-specific memory T cells would
be a careful selection of recipient-donor pairs by choosing recipients with low
memory for the respective donor. However, this is not too easy to implement
considering the overall shortage of donor organs and the fact, that donor-
recipient pairs are only chosen in advance in living donation. On the other hand,
the evaluation of donor-reactive memory T cell frequency and the strength of
their reaction might enable tailoring a more individualized immunosuppression
according to the risk the recipient is at (Ford and Larsen 2011).
Another or an additional option is the use of new therapies directed specifically
against memory T cells. Targeting CD2 or LFA-1 has been shown to prevent
allograft rejection by memory T cells. CD2 is expressed on effector memory T
cells, which are able to mediate costimulation blockade resistant allograft rejec-
tion. Blockade of CD2 in combination with CTLA-4-Ig and mTOR blockade
resulted in renal allograft survival greater than 90 days even after discontinua-
tion of treatment (Weaver et al. 2009). Memory T cells are able to traffic very
Discussion 86
quickly into allografts (12 - 24 hours post transplantation) (Schenk et al. 2008).
Blockade of LFA-1 with an antibody was able to prevent this early infiltration
(Setoguchi et al. 2009) and was effective to inhibit donor-reactive memory
T cell responses when combined with costimulation blockade (Kitchens et al.
2011). But one has to consider that long-term targeting memory T cell activ-
ity is on the expense of a loss of the memory response against environmental
pathogens. However, in a non-human primate model for islet transplantation
an approach to use LFA-1 induction therapy combined with belatacept seemed
promising (Badell et al. 2010). Our findings about DNAM-1 for allospecific T
cell priming and its interplay with LFA-1 (Shibuya et al. 2003) suggest that
this molecule might also be a target for such a purpose.
Costimulation blockade in the clinics
Costimulation blockade for tolerance induction
The final goal of transplantation immunology research is to achieve a state of
donor-specific tolerance, which is defined as lack of acute and chronic allograft
rejection in the absence of ongoing immunosuppressive therapy and an intact
immune reactivity to pathogens and cancer. With such a situation in a patient,
it would be possible to avoid toxicities of current immunosuppressive therapies,
opportunistic infections, and cancer. Thus, major obstacles for long term allo-
graft survival that patients are facing today would be abolished. Costimulation
blockade is a promising tool to be used together with DST or bone marrow
transplantation in order to induce mixed chimerism in experimental models.
However, it has been shown, that tolerance induction with DST under costimu-
lation blockade is broken after time by new T cells leaving the thymus (Iwakoshi
et al. 2001).
The mixed chimerism approach allows a more stable state of tolerance. The
experimental protocols were translated into a clinical setting, leading to a study
with five patients receiving combined bone marrow and kidney transplantation
from HLA-mismatched donors (Kawai et al. 2008). Four of the five patients
have accepted their renal allografts and are off immunosuppressive drugs since
several years. The regimen these patients received contained cyclophosphamide
for myelosuppression, anti-CD2 antibodies, cyclosporine A, and thymic irradi-
ation for reduction and blockade of peripheral T cells prior to kidney trans-
plantation and subsequent donor bone marrow transfusion (Kawai et al. 2008).
After transplantation recipients received cyclosporine A for a period of some
months. In some patients rituximab (a B cell depleting antibody), was added to
the induction protocol and steroids were given for ten days following transplan-
tation (Kawai et al. 2008). Interestingly, all patients lost chimerism over time,
which did not inevitably lead to rejection of the kidney graft and reactivation
of donor responsiveness. For the patients a life free of immunosuppressive drugs
it is now a big advantage in quality of life and health.
On the other hand there are critics, who would not describe the state of these
patients as one of a donor-specific tolerance. Halloran et al. suspect that the
invasive induction therapy used here induces changes in the lymphoid system
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that might last for years (Halloran et al. 2008). Thus, they speculate the pa-
tients still ”suffer” from immunosuppression and therefore are not able to reject
their kidney grafts and still remain at risk for infections or malignancies. If they
are right, one will only be able to tell after time.
Indeed, it is true that the intense induction treatment has made the approach
untranslatable to a larger patient cohort. Furthermore, the mixed chimerism
approach in this setup is limited to living donation. Studies are now undertaken
to solve this problem and transplant donor bone marrow at a later time point
after transplantation (Koyama et al. 2007). Thus, new strategies to induce
mixed chimerism in patients have to be evolved and costimulation blockade
could be a part of them.
Costimulation blockade for maintenance immunosuppression
Costimulation blockade on the other hand is also an option for maintenance
therapy in allograft recipients. With well designed biologics directed against
costimulatory molecules some of the toxic effects of current therapy options
could be avoided. An example for this is belatacept, which is used in clinics for
renal transplantation in combination with mycophenolic acid and steroids in or-
der to avoid calcineurin inhibitor toxicity. Phase III trials have shown reduced
signs of calcineurin inhibitor nephrotoxicities after one year and improved kid-
ney function compared to a control group receiving cyclosporine A even after
3 year follow-up (Vincenti et al. 2011). Also the incidence of new onset dia-
betes and dislipidemia were reduced in the groups not receiving cyclosporine
A (Vincenti et al. 2011). Unfortunately in the belatacept treated groups a
higher incidence of post-transplant lymphoproliferative disorder (PTLD) was
observed. This was most elevated in the group receiving a high dose of belat-
acept and mainly restricted to Epstein-Barr virus negative patients receiving a
graft from a seropositive donor, leading to B cell lymphomas (Vincenti et al.
2011).
Another risk factor is, as discussed above, that belatacept does not only block
CD28 signaling but also CTLA-4 and PD-L1 signals, which are important for
regulating T cell proliferation. Furthermore, CD28 signaling leading to IL-2 pro-
duction is essential for the development of Tregs (Pilat et al. 2011). CTLA-4 is
constitutively expressed on Tregs, and is critical for their suppressor function
(Wing et al. 2008). Thus, belatacept in high doses might block Treg induction
and activity. Finally CD28 signaling has been shown to prevent Th17 induc-
tion (Bouguermouh et al. 2009). Blocking CD28 might therefore lead to a
stronger induction of this proinflammatory Th subset. Thus, the use of only
CD28 blockade alone might not be the most efficient way to use costimulatory
blockade in the future.
Combining belatacept with an agent blocking CD40 may prevent some of the
mentioned adverse effects. Belatacept might be used in lower doses, when
combined with CD40 blockade, thereby preventing complete masking of the
beneficial effects of CTLA-4 on Tregs. Furthermore, as we and others have
shown, Th17 induction is dependent on CD40 signaling (Iezzi et al. 2009), thus
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might be reduced when blocking also the CD40 pathway. Additional to this,
it might be useful to block a costimulatory pathway, which is important for
T-B-cell interaction (e.g. CD40), to avoid the formation of de novo allospecific
antibodies.
A blocking antibody directed against CD40 (4D11) is going to clinical phase
II trials right now, and the results are going to give a deeper insight in the
efficacy of this approach. Our development of a blocking F(ab)-fragment di-
rected against murine CD40 might help alongside to understand the mechanistic
differences between CD40 and CD154 blockade and develop new protocols for
tolerance induction.
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